

05.05.2021

09:00 - 20:00 **Type: ePoster session** **On-Demand ePoster Display**
Title: ePoster Display Session

- 09:00 - 09:00 **6P - 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer**
H. Dar¹, A. Johansson², A. Nordensköld³, A. Iftimi⁴, C. Yau⁵, G. Perez-Tenorio⁶, C. Benz⁵, B. Nordenskjöld⁶, O. Stål⁶, L. Esserman⁵, T. Fornander², L. Lindström², ¹ Stockholm, SE, ²Karolinska Institute, Stockholm, SE, ³Institute of Clinical Sciences, Gothenburg, SE, ⁴University of Valencia, Valencia, ES, ⁵University of California San Francisco, San Francisco, US, ⁶Linköping University, Linköping, SE
- 09:00 - 09:00 **7P - An optimized Breast Cancer Index node-positive (BCIN) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR) node-positive breast cancer**
G.-J. Liefers¹, I. Noordhoek², Y. Zhang³, D. Sgroi⁴, H. Putter², K. Treuner³, J. Wong³, E. Meershoek-Klein Kranenbarg², M. Duijm-De Carpentier², C. Van De Velde², C. Schnabel³, ¹ Leiden, NL, ²Leiden University Medical Center, Leiden, NL, ³Biotheranostics, Inc., San Diego, US, ⁴Massachusetts General Hospital, Boston, US
- 09:00 - 09:00 **8P - Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial**
L. Malorni¹, M. Benelli², F. Galardi², C. Biagioni², G. Curigliano³, A. Minisini⁴, E. Moretti², E. Risi², F. De Luca², A. McCartney⁵, A. Di Leo², L. Biganzoli², I. Migliaccio², ¹ Prato, IT, ²Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, ³European Institute of Oncology, Milan, IT, ⁴Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ⁵Monash University, Melbourne, AU
- 09:00 - 09:00 **9P - BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation**
Y. Wang¹, E. Rosenberg², G. Dackus³, A. Broeks², S. Cornelissen², P. Van Diest³, M. Hauptmann⁴, N. Ter Hoeve³, V. De Jong², K. Jozwiak⁴, E. Koop⁵, P. Nederlof², M. Opdam², S. Siesling⁶, N. Stathonikos³, A. Voogd⁷, W. Vreuls⁸, M. Kok², S. Linn², M. Schmidt², ¹ Amsterdam, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³University Medical Center Utrecht, Utrecht, NL, ⁴Brandenburg Medical School Theodor Fontane, Brandenburg, DE, ⁵Gelre Ziekenhuizen, Apeldoorn, NL, ⁶Netherlands Comprehensive Cancer Organization, Utrecht, NL, ⁷Maastricht University Medical Center, Maastricht, NL, ⁸Canisius Wilhelmina Ziekenhuis, Nijmegen, NL
- 09:00 - 09:00 **10P - The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2 breast cancers**
N. Fusco¹, K. Venetis², M. Invernizzi³, D. Gambini⁴, C. Blundo⁴, L. Runza⁴, S. Ferrero⁵, E. Guerini Rocco², ¹ Milan, IT, ²IEO - Istituto Europeo di Oncologia, Milan, IT, ³University of

Eastern Piedmont, Novara, IT, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, IT, ⁵University of Milan, Milan, IT

- 09:00 - 09:00 **11P - A Breast Cancer Index (BCI) prognostic model for N0 HR⁺ breast cancer optimized for late distant recurrence**
J. Bartlett¹, Y. Zhang², I. Ahmed³, K. Treuner², T. Piper⁴, S. Pirrie³, A. Brufsky⁵, D. Sgroi⁶, C. Schnabel², D. Rea³, ¹Toronto, CA, ²Biotheranostics, Inc., San Diego, US, ³University of Birmingham, Birmingham, GB, ⁴University of Edinburgh, Edinburgh, GB, ⁵Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, ⁶Massachusetts General Hospital, Boston, US
- 09:00 - 09:00 **12P - The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer**
M. Silvestri¹, A. Vingiani², L. De Cecco³, A. Belfiore³, E. Ortolan³, S. Veneroni³, A. Trama³, V. Cappelletti³, G. Pruneri², S. Di Cosimo³, ¹MILANO, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori; University of Milan, MILANO, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori, MILANO, IT
- 09:00 - 09:00 **13P - Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)**
A. Noske¹, K. Schwamborn², S. Foersch³, K. Steiger², M. Kiechle⁴, S. Karapetyan², D. Oettler⁵, A. Hapfelmeier², W. Roth³, W. Weichert², ¹Munich, DE, ²TUM - Technical University of Munich, Munich, DE, ³Johannes Gutenberg University Mainz, Mainz, DE, ⁴Klinikum Rechts der Isar - TUM - Technical University of Munich, Munich, DE, ⁵MSD Sharp & Dohme GmbH, Haar, DE
- 09:00 - 09:00 **14P - Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark**
A. Vethencourt Casado¹, E. Trinidad², C. Gómez Aleza², S. Pernas Simon³, A. Petit⁴, T. Soler⁴, A. Urruticoechea⁵, A. Gumà Martínez⁴, A. García-Tejedor⁴, M.J. Pla⁴, C. Capó⁶, M. Gil Gil³, A. Stradella³, A. Fernández³, S. Recalde Penabad³, M. Cejuela³, S. Vazquez³, A. Iserte³, C. Falo³, E. Gonzalez-Suarez², ¹Hospitalet de Llobregat, ES, ²IDIBELL Institut d'investigació biomèdica de Bellvitge, Barceloma, ES, ³ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁴Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, ⁵Onkologikoa, Donostia, ES, ⁶Hospital de Viladecans, Viladecans, ES
- 09:00 - 09:00 **15P - The combined influence of receptor subtype, grade and TN status on breast cancer survival in recently treated women with non-metastatic disease in Norway**
A. Johansson¹, C. Trewin², I. Fredriksson³, K. Reinertsen⁴, H. Russnes⁴, G. Ursin², ¹Stockholm, SE, ²Cancer Registry of Norway, Oslo, NO, ³Karolinska Institutet, Stockholm, SE, ⁴Oslo University Hospital, Oslo, NO
- 09:00 - 09:00 **16P - Understanding the biologic determinants of ribociclib efficacy in breast cancer**
F. Brasó-Maristany¹, M. Palafox², L. Monserrat², M. Bellet Ezquerra², M. Oliveira², M.

Capelán², P. Galván¹, D. Martínez¹, N. Chic³, C. Viaplana², R. Dienstmann⁴, P. Nuciforo², C. Saura Manich⁵, A. Prat⁶, V. Serra⁴, ¹IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵Medical Oncology Department, Vall d'Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁶Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES

09:00 - 09:00 **17P - Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials**

J. Furlanetto¹, M. Untch², B. Sinn³, B. Lederer¹, A. Schneeweiss⁴, V. Mueller⁵, M. Van Mackelenbergh⁶, E. Stickeler⁷, P.A. Fasching⁸, C. Schem⁹, T. Karn¹⁰, F. Marmé¹¹, V. Nekljudova¹², S. Loibl¹², ¹German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ²Helios Klinikum Berlin Buch, Berlin, DE, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE, ⁵UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁶Universitätsklinikum Schleswig-Holstein, Kiel, DE, ⁷Uniklinik RWTH Aachen, Aachen, DE, ⁸University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nuremberg, Erlangen, DE, ⁹Mammazentrum Hamburg, Hamburg, DE, ¹⁰Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹¹UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ¹²GBG, Neu-Isenburg, DE

09:00 - 09:00 **18P - Age-related breast cancer gene expression signature with strong prognostic value**

L. Ingebriksen¹, E. Wik², L. Akslen³, ¹Bergen, NO, ²University of Bergen, Bergen, NO, ³Haukeland University Hospital, Bergen, NO

09:00 - 09:00 **19P - A dichotomous oncogenic role of the splicing factor SF3A3 in MYC-driven triple-negative breast cancer**

A. Bosch¹, M. Ciesla², P. Cao Thi Ngoc², S. Mutukumar^{1,2}, G. Honeth², J. Staaf², D. Incarnato³, K. Pietras², C. Bellodi², ¹Lund, SE, ²Lund University, Lund, SE, ³University of Groningen, Groningen, NL

09:00 - 09:00 **20P - Is evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutational status on circulating tumour DNA (ctDNA) by liquid biopsy ready for prime-time? A systematic review and an individual patient meta-analysis**

L. Castellana¹, V. Gristina², A. Galvano², M. La Mantia², L. Insalaco², N. Barraco², S. Cutaia², F. Iacono², G. Santanelli², A. Cucinella², G. Madonia², M.R. Ricciardi², M.C. Lisanti², V. Calò², M. Castiglia², A. Perez², S. Cusenza², S. Rizzo², A. Russo², V. Bazan², ¹Palermo, IT, ²AOU Policlinico "Paolo Giaccone", Palermo, IT

09:00 - 09:00 **21P - BACH1 and HIF1 β ; predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)**

V. Vladimirova¹, A. Schneeweiss², C. Jackisch³, K. Weber⁴, C. Denkert⁵, S. Schmatloch⁶,

T. Karn⁷, P.A. Fasching⁸, S. Braun³, C. Szeto⁹, B. Sinn¹⁰, M. Van Mackelenbergh¹¹, C. Schem¹², E. Stickeler¹³, P. Soon-Shiong⁹, F. Marmé¹⁴, V. Mueller¹⁵, M. Untch¹⁶, V. Nekljudova¹, S. Loibl¹, ¹GBG, Neu-Isenburg, DE, ²Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE, ³Sana Klinikum Offenbach, Offenbach am Main, DE, ⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ⁵Philipps-University Marburg, Marburg, DE, ⁶Elisabeth-Krankenhaus Kassel, Kassel, DE, ⁷Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁸University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nurembergen, Erlangen, DE, ⁹ImmunityBio Inc, Santa Cruz, US, ¹⁰Charité - Universitätsmedizin Berlin, Berlin, DE, ¹¹Universitätsklinikum Schleswig-Holstein, Kiel, DE, ¹²Mammazentrum Hamburg, Hamburg, DE, ¹³Uniklinik RWTH Aachen, Aachen, DE, ¹⁴UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ¹⁵UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ¹⁶Helios Klinikum Berlin Buch, Berlin, DE

09:00 - 09:00 **27P - MiR-221/222 may enhance epithelial-mesenchymal transition and tamoxifen resistance by down-regulating GATA3**

L. Yuanke¹, Q. Xie², Z.-H. Wang³, W. Wang⁴, Z.-M. Xie⁵, X.-F. Xiao³, D. Zeng⁶, H. Lin⁷, ¹??, CN, ²Shantou University Medical College, Shantou, CN, ³The First Affiliated Hospital of Shantou University Medical College, Shantou, CN, ⁴Cancer Hospital of Shantou University Medical College, Shantou, CN, ⁵Cancer Hospital of Shantou University Medical College, Shantou, CN, ⁶Shantou University Medical College, Shantou, CN, ⁷The First Affiliated Hospital of Shantou University Medical College, Shantou, CN

09:00 - 09:00 **28P - EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy**

J. Leichsenring¹, V. Vladimirova², C. Solbach³, T. Karn⁴, B. Ataseven⁵, B. Sinn⁶, J. Barinoff⁷, V. Mueller⁸, J.-U. Blohmer⁶, C. Schem⁹, K. Engels¹⁰, F. Marmé¹¹, A. Fissler-Eckhoff¹², P.A. Fasching¹³, E. Stickeler¹⁴, M. Van Mackelenbergh¹⁵, C. Denkert¹⁶, A. Stenzinger¹⁷, S. Loibl², S. Gröschel¹⁸, ¹Heidelberg, DE, ²GBG, Neu-Isenburg, DE, ³University Clinic Frankfurt, Frankfurt am Main, DE, ⁴Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁵Universitätsklinikum München (LMU) and Kliniken Essen-Mitte, München and Essen, DE, ⁶Charité - Universitätsmedizin Berlin, Berlin, DE, ⁷St. Gertrauden-Krankenhaus, Berlin, DE, ⁸UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁹Mammazentrum Hamburg, Hamburg, DE, ¹⁰Center for Pathology, Cytology and Molecular Pathology, Neuss, Neuss, DE, ¹¹UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ¹²Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, DE, ¹³University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nurembergen, Erlangen, DE, ¹⁴Uniklinik RWTH Aachen, Aachen, DE, ¹⁵Universitätsklinikum Schleswig-Holstein, Kiel, DE, ¹⁶Philipps-University Marburg, Marburg, DE, ¹⁷Universitätsklinikum Heidelberg, Heidelberg, DE, ¹⁸Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, DE

09:00 - 09:00 **29P - Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer**

M. Bos¹, S. Lam², J. Helmijr³, C. Beaufort⁴, A. Jager⁵, J. Martens⁴, E. Boven², M. Jansen⁴,

S. Sleijfer⁴, ¹ Rotterdam, NL, ²Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, Amsterdam, NL, ³Erasmus MC Cancer Institute, Amsterdam, NL, ⁴Erasmus MC Cancer Institute, Rotterdam, NL, ⁵Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

- 09:00 - 09:00 **30P - Expression signature of Let-7a, miR-34a and miR-486-5p in young triple-negative breast cancer patients overexpressing PDL1: A step towards precision immuno-oncology**
C. Kiriacos¹, M. Khedr², M. Tadros², H. Hafez³, R. Youness², ¹ Cairo, EG, ²German University in Cairo, Cairo, EG, ³Faculty of Medicine, Kasr El-Ainy, Cairo University, Cairo, EG
- 09:00 - 09:00 **31P - Association between breast cancer protein truncating variants and febrile neutropenia breast cancer patients treated with taxane or anthracycline chemotherapy in Singapore**
S.S. Ong¹, P.J. Ho², A. Khng², G.H. Lim³, S.H. Lim³, S.G.W. Ow⁴, J.S. Pang³, B. Kiat Tee Tan⁵, E.Y. Tan⁶, S.M. Tan⁷, V. Kiak Mien Tan⁵, F.Y. Wong⁸, J. Li², M. Hartman⁹, ¹ Singapore, SG, ²A*STAR - Genome Institute of Singapore (GIS), Singapore, SG, ³KK Women's and Children's Hospital, Singapore, SG, ⁴National University Cancer Institute, Singapore, Singapore, SG, ⁵Singapore General Hospital, Singapore, SG, ⁶Tan Tock Seng Hospital, Singapore, SG, ⁷Changi General Hospital, Singapore, SG, ⁸National Cancer Centre Singapore, Singapore, SG, ⁹National University of Singapore and National University Health System, Singapore, SG
- 09:00 - 09:00 **32P - PIK3CA exon 9 and 20 mutations in early luminal breast cancer: Case series and review of the literature**
I. Betancor Fernández¹, C. González García², A. Ramos-Navas², E. Salido Ruiz³, ¹ San Cristóbal de La Laguna, ES, ²Hospital Universitario de Canarias, San Cristóbal de La Laguna, ES, ³Hospital Universitario de Canarias, San Cristóbal de la Laguna, ES
- 09:00 - 09:00 **33P - Epigenetic biomarkers ID1, HOXB2 and ATOH8 could predict response to chemotherapy and prognosis in early breast cancer**
V. Quiroga Garcia¹, S. Moran², C. Queralt³, S. Cabrero⁴, A. Bernat⁵, A. Ferrando Diez⁶, L. Perez⁶, B. Cirauqui Cirauqui³, E. Felip³, I. Teruel-Garcia³, M. Romeo Marin⁷, A. Pous⁶, E. Castellà⁶, A. Martinez-Cardús⁵, M. Margeli⁸, ¹ Badalona, ES, ²Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Hospitalet, ES, ³ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁴Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, ES, ⁵Badalona·Applied Research Group in Oncology (B·ARGO), Badalona, ES, ⁶Hospital Universitario Germans Trias i Pujol, Badalona, ES, ⁷Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, ⁸ICO-Badalona. Hospital Germans Trias i Pujol. GEICAM, Spanish Breast Cancer Group, Badalona, ES
- 09:00 - 09:00 **34P - New pathogenic germline mutation in ATM gene in Khakass breast cancer patients**
P. Gervas, Tomsk, RU
- 09:00 - 09:00 **35P - Prognostic impact of cytotoxic CD4 T cells (CD4 CTL) in tumour immune**

microenvironment of breast cancer patients

K. Shohdy¹, D. Almeldin², R. Ghaly², L. Kassem², O. Pagani³, ¹ Cairo, EG, ²Kasr Al Ainy School of Medicine - Cairo University - Faculty of Medicine, Cairo, EG, ³HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH

09:00 - 09:00 **36P - The association between tri-nucleotide-repeat containing 9 (TNRC9) /LOC643714 genetic variations and breast cancer in Egyptian females**

A. Alhanafy¹, M. El-Shafie², A. Abdu Allah², S. Rizk², M. Habieb², ¹ Shebeen El-Kom, EG, ²Faculty of Medicine - Menoufia University, sheben elkom, EG

09:00 - 09:00 **37P - Genetic alteration in KLK5 associated with individual mode of breast cancer invasion**

N. Novikov¹, A. Fokin², S. Zolotaryova³, A. Kiselev³, A. Gautreau², E. Denisov⁴, ¹ Tomsk, RU, ²Ecole Polytechnique, Palaseau, FR, ³Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RU, ⁴Tomsk Cancer Research Institute RAMS, Tomsk, RU

09:00 - 09:00 **38P - Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis**

J. Prabhu¹, S. Patil¹, S. Rajarajan¹, A. Ce¹, M. Nair¹, A. Alexander¹, R. Ramesh², S. Bs³, T. Sridhar¹, ¹St Johns Research Institute, Bangalore, IN, ²St Johns Medical College Hospital, Bangalore, IN, ³Shankara Cancer Hospital & Research Centre, Bangalore, IN

09:00 - 09:00 **39P - Applicability of a pathology-based combined model NOLUS (NON-LUMINAL Score) in HR⁺/HER2⁻ early breast cancer patients treated at a tertiary referral center in Mexico**

A. Valenzuela-Vidales¹, A. Armengol-Alonso², ¹ Ciudad de Mexico, MX, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, CDMX, MX

09:00 - 09:00 **40TiP - SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER⁺/PgR⁺/HER2⁻) early breast cancer (EBC)**

M. Bellet Ezguerra¹, S. Morales Murillo², A. Gasol Cudos², K. Amillano³, N. Chic⁴, X. González-Farré⁵, P. Villagrasa⁶, J. Ferrero-Cafiero⁶, T. Pascual⁷, A. Prat⁸, C. Lange⁹, C. Saura Manich¹⁰, ¹Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Hospital Universitario Arnau de Vilanova, Lleida, ES, ³Hospital Universitari Sant Joan de Reus, Reus, Spain, Reus, ES, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁵Hospital General de Catalunya / Institut Oncològic Dr. Rosell / SOLTI Breast Cancer Research Group, Sant Cugat del Vallés, ES, ⁶SOLTI Breast Cancer Research Group, Barcelona, ES, ⁷SOLTI Breast Cancer Research Group, bcn, ES, ⁸Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES, ⁹University of Minnesota, Minneapolis, US, ¹⁰Medical Oncology Department, Vall d'Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

09:00 - 09:00 **45P - Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III**

ExteNET trial

A. Chan¹, B. Moy², J. Mansi³, M. Gnant⁴, C. Barrios⁵, R. Separovic⁶, A. Guerrero-Zotano⁷, I. Gore⁸, J. Smith⁹, R. Bryce¹⁰, F. Xu¹⁰, A. Wong¹⁰, M. Martin¹¹, F.A. Holmes¹², ¹Breast Cancer Research Centre BCRC - WA, Nedlands, AU, ²Massachusetts General Hospital Cancer Center, Boston, US, ³Guy's and St. Thomas' Hospital NHS Foundation Trust and Biomedical Research Centre, King's College London, London, GB, ⁴Medical University of Vienna, Vienna, AT, ⁵Centro de Pesquisa em Oncologia HSL, PUCRS, Porto Alegre, BR, ⁶University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, HR, ⁷Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁸Alabama Oncology, Birmingham, US, ⁹Compass Oncology, Portland, US, ¹⁰Puma Biotechnology Inc., Los Angeles, US, ¹¹Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, ES, ¹²Texas Oncology, US Oncology, Houston, US

09:00 - 09:00

46P - Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

S.-A. Im¹, A. Tan², A. Mattar³, R. Colomer⁴, D. Stroyakovskii⁵, Z. Nowecki⁶, M. De Laurentiis⁷, J.-Y. Pierga⁸, K.H. Jung⁹, C. Schem¹⁰, C. Aguila¹¹, T. Badovinac Crnjevic¹¹, S. Heeson¹², M. Shivhare¹², A. Alexandrou¹², E. Restuccia¹¹, C. Jackisch¹³, ¹SNUH-Seoul National University Hospital, Seoul, KR, ²Levine Cancer Institute, Atrium Health, Charlotte, US, ³Hospital Pérola Byington, São Paulo, BR, ⁴Hospital Universitario La Princesa, Madrid, ES, ⁵City Clinical Oncology Hospital 62, Moscow, RU, ⁶Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁷Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Napoli, IT, ⁸Université de Paris, Paris, FR, ⁹Asan Medical Center, Seoul, KR, ¹⁰Mammazentrum Hamburg, Hamburg, DE, ¹¹F. Hoffmann-La Roche Ltd, Basel, CH, ¹²Roche Products Limited, Welwyn Garden City, GB, ¹³Klinikum Offenbach GmbH, Offenbach, DE

09:00 - 09:00

47P - The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 survey

V. Memoli¹, D. Rey², S. Lauzier³, J. Mancini², A.-D. Bouhnik⁴, ¹Marseille, FR, ²UMR 1252 SESSTIM AMU, INSERM, IRD, Marseille, FR, ³Population Health and Optimal Health Practices research Axis, Quebec, CA, ⁴SESSTIM-INSERM UMR 1252-IRD-AMU, Marseille, FR

09:00 - 09:00

48P - Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE

Y.-S. Yap¹, S.-B. Kim², J. Chiu³, E. Lim⁴, R. Broom⁵, Z. Liu⁶, Y. Sagara⁷, T.-Y. Chao⁸, S. Sherwood⁹, R. Mcnaughton⁹, R. Wei⁹, M. Toi¹⁰, ¹Singapore, SG, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Queen Mary Hospital, Hong Kong, HK, ⁴St Vincent's Hospital and Garvan Institute of Medical Research, Sydney, AU, ⁵Auckland City Hospital, Auckland, NZ, ⁶Affiliated Cancer Hospital of Zhengzhou university, Henan Cancer Hospital, Zhengzhou, CN, ⁷Social Medical Corporation Hakuai Sagara Hospital, Kagoshima, JP, ⁸Taipei Medical University - Shuang Ho Hospital, New Taipei City, TW, ⁹Eli Lilly, Indianapolis, US, ¹⁰Kyoto University-Graduate school of medicine, Kyoto, JP

- 09:00 - 09:00 **49P - Socioeconomic status and survivorship in premenopausal breast cancer patients: A population-based cohort study**
C. Hjorth¹, D. Cronin-Fenton², P. Damkier³, T. Lash⁴, H. Sørensen², B. Ejlersten⁵, ¹Aarhus N, DK, ²Aarhus University Hospital, Aarhus N, DK, ³University of Southern Denmark, Odense, DK, ⁴Rollins School of Public Health, Emory University, Atlanta, US, ⁵Rigshospitalet, Glostrup, DK
- 09:00 - 09:00 **59P - Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study**
J. Hendry¹, S. Ali², O. Ahmed³, H. Chalchal⁴, A. El-Gayed³, K. Haider³, N. Iqbal³, K. Johnson³, D. Le³, B. Maas³, M. Manna³, M. Pauls³, M. Salim⁴, A. Sami³, P. Wright³, M. Younis³, S. Ahmed³, ¹Saskatoon, CA, ²University of Saskatchewan, Saskatoon, CA, ³Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, ⁴Allan Blair Cancer Center, Regina, CA
- 09:00 - 09:00 **60P - Real-life use of Oncotype DX Breast Recurrence Score; test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)**
I. Fernandez Perez¹, S. Antolin Novoa², L. De Paz Arias³, L. Vazquez Tuñas⁴, M.E. Perez Lopez⁵, S. Varela Ferreiro⁶, A. Gonzalez Quintas⁷, C. Senin Estor⁸, J. Cueva Banuelos⁹, C. Hagen¹⁰, L. Inglada-Pérez¹¹, D. Pereiro¹², L. Calvo-Martinez², I. Carou⁴, L. Iglesias Rey¹³, A. Saenz De Miera⁸, T. García-Caballero¹⁴, ¹Hospital Alvaro Cunqueiro. GEICAM Breast Cancer Group, Vigo, ES, ²CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ³Complejo Hospitalario of Ferrol, Madrid, ES, ⁴Complejo Hospitalario de Pontevedra, Pontevedra, ES, ⁵Complejo Hospitalario Universitario Ourense, A Coruña, ES, ⁶HULA - Hospital Universitario Lucus Augusti, Lugo, ES, ⁷Fundacion Centro Oncologico de Galicia, A Coruña, ES, ⁸Hospital Povisa, Vigo, ES, ⁹CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ¹⁰Genomic Health International Sarl, Geneva, CH, ¹¹Universidad Complutense de Madrid, Madrid, ES, ¹²CHUVI - Complejo Hospitalario Universitario de Vigo, Vigo, ES, ¹³Complejo Hospitalario Universitario de Ourense, Ourense, ES, ¹⁴Universidade de Santiago de Compostela, Santiago de Compostela, ES
- 09:00 - 09:00 **61P - Estimating the cost of adjuvant chemotherapy in ER+/HER2- early breast cancer and distant recurrence of breast cancer in the UK**
V. Berdunov¹, S. Millen², A. Paramore², S. Reynia², N. Fryer², J. Griffin³, N. Georges², ¹London, GB, ²Waterloo, London, GB, ³East Molesey, Surrey, GB
- 09:00 - 09:00 **62P - Influence of PAM50 on therapeutic decisions in patients with early-stage luminal breast cancer in a single centre**
A. Olivares¹, R. Escala Cornejo², M. García Muñoz³, L. Figuero-Perez³, J. Martín Vallejo⁴, M. Sancho De Salas³, M.A. Gómez Muñoz³, E. Escalera Martín³, J. Claros Ampuero³, Á. López Gutiérrez³, E. Terán Brage³, B. Barrios Collado⁵, D. Casado Elia⁶, G. Martín García³, R. Seijas Tamayo³, J.J. Cruz Hernandez⁵, C.A. Rodríguez⁷, ¹Salamanca, ES, ²Complejo Asistencial de Avila - Hospital Nuestra Señora de Sonsoles Urgencias, Ávila, ES, ³University Hospital of Salamanca, Salamanca, ES, ⁴University of Salamanca, Salamanca, ES, ⁵IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ⁶Hospital Universitario de Salamanca, Salamanca, ES, ⁷Hospital Universitario de

Salamanca-IBSAL. GEICAM, Spanish Breast Cancer Group, Salamanca, ES

09:00 - 09:00

64P - Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer

S. Di Cosimo¹, R. Miceli¹, P. Baili¹, M. Sant¹, G. Pruneri², A. Vingiani², S. Folli¹, M. Bini¹, M. De Santis¹, G. Scaperrotta¹, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, MILANO, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori; University of Milan, MILANO, IT

09:00 - 09:00

65P - Patient follow-up of NEOVATTL study

B. Vieites¹, M. López-García², M. Martín-Salvago³, C. Ramírez-Tortosa³, R. Rezola⁴, M. Sancho De Salas⁵, L. López Vilaró⁶, F. Vilardell Villellas⁷, O. Burgués⁸, B. Fernández-Rodríguez⁹, L. Alfaro Galán², V. Peg¹⁰, ¹ Seville, ES, ²IBIS - Instituto de Biomedicina de Sevilla - Campus Hospital Universitario Virgen del Rocío, Seville, ES, ³Hospital Universitario Materno-Infantil, Jaén, ES, ⁴Onkologikoa Kutxa Fundazioa, Donostia, ES, ⁵University Hospital of Salamanca, Salamanca, ES, ⁶Hospital de La Santa Creu I Sant, Barcelona, ES, ⁷Hospital Universitario Arnau de Vilanova, Lleida, ES, ⁸Hospital Clínico Universitario de, Valencia, ES, ⁹Complejo Hospitalario,, Santiago de Compostela, ES, ¹⁰Hospital Universitari Vall, Barcelona, ES

09:00 - 09:00

66P - Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto

S.I. Labidi-Galy¹, A. Schneeweiss², H.P. Sinn³, J.-U. Blohmer⁴, L. Romanens⁵, D.-M. Zahm⁶, J. Huober⁷, D. Dohnal⁸, T. Link⁹, C. Hanusch¹⁰, C. Jackisch¹¹, P.A. Fasching¹², C. Solbach¹³, K. Rhiem¹⁴, C. Denkert¹⁵, K. Weber¹⁶, B. Lederer¹⁶, M. Untch¹⁷, S. Loibl¹⁸, J. Furlanetto¹⁶, ¹ Geneva, CH, ²Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE, ³University Hospital Heidelberg, Heidelberg, DE, ⁴Charité - Universitätsmedizin Berlin, Berlin, DE, ⁵University of Geneva, Geneva, CH, ⁶SRH Wald-Klinikum Gera, Gera, DE, ⁷University Hospital Ulm, Ulm, DE, ⁸Dres. Dohnal and Partner, Düsseldorf, DE, ⁹Medical Faculty and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, DE, ¹⁰Rotkreuzklinikum, München, DE, ¹¹Klinikum Offenbach GmbH, Offenbach, DE, ¹²University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nuremberg, Erlangen, DE, ¹³University Clinic Frankfurt, Frankfurt am Main, DE, ¹⁴University Hospital Cologne, Köln, DE, ¹⁵Philipps-University Marburg, Marburg, DE, ¹⁶German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ¹⁷Helios Klinikum Berlin Buch, Berlin, DE, ¹⁸GBG, Neu-Isenburg, DE

09:00 - 09:00

67P - The role of FDG PET/CT to omit sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer

E. Tanrikulu Simsek¹, E. Çoban¹, E. Atag¹, S. Gungor², M. Sari³, G. Gurleyik⁴, ¹Medical Oncology, Haydarpasa Numune Training and Research Hospital, Istanbul, TR, ²Nuclear Meicine, Istanbul Medeniyet University, Istanbul, TR, ³Medical Oncology, Haydarpasa Numune Training and Research Hospital, Istanbul, Istanbul, TR, ⁴Surgical Oncology, Haydarpasa Numune Training and Research Hospital, Istanbul, TR

09:00 - 09:00

68P - A meta-analysis of the efficacy of adding immune checkpoint inhibitors to

neoadjuvant chemotherapy against triple-negative breast cancer

Y. Li¹, L. Xing², X. Yin², H. Li², G. Ren², ¹ Chongqing, CN, ²The first Affiliated Hospital of Chongqing Medical University, Chongqing, CN

09:00 - 09:00 **69P - Real world impact of the introduction of targeted axillary dissection (TAD) following neo-adjuvant chemotherapy (NAC)**

G. Mohammadi-Zaniani¹, R. Mclean², A. Pieri², M. Verrill³, N. Cresti³, H. Cain², ¹ Newcastle Upon Tyne, GB, ²Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, GB, ³Northern Centre For Cancer Care, Newcastle Upon Tyne, GB

09:00 - 09:00 **70P - Neoadjuvant chemotherapy in breast cancer in the last 2 decades: Are we improving survival? Retrospective analysis in a single institution**

J. Ponce¹, S. Delgado², H. Ballester², T. Martín², G. Peiro², F. Aranda², M. Niveiro², Y. Montoyo², N. Gómez², J. Sánchez², A. Rodríguez-Lescure³, D. Parra², L. Gomez², I. Lozano², B. Massuti², ¹Hospital General Universitario de Alicante, Alicante, ES, ²Hospital General Universitario de Alicante, ISABIAL, Alicante, ES, ³Hospital General Universitario de Elche. GEICAM, Spanish Breast Cancer Group, Elche, ES

09:00 - 09:00 **71P - Impact of body mass index (BMI) on pathological complete response (pCR) and survival of breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC)**

D. Aguiar Bujanda¹, L. Ros Sanjuan², D. Perez Cabrera², L. Croissier Sanchez², M. Mori De Santiago², M. Hernandez Sosa², A. Vargas Prado², S. Galvan Ruiz², C. Antonilli Perez², R. Ten Benajes², B. Fox², R. Martinez Garcia-Cervantes², G. Rubio Romero², R. Hanselmann², S. Saura Grau², ¹ Las Palmas de Gran Canaria, ES, ²Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, ES

09:00 - 09:00 **72TiP - ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast**

E. Agostinetti¹, M. Paesmans², L. Ameye², I. Veys², L. Buisseret³, P. Neven⁴, D. Taylor⁵, C. Fontaine⁶, F.P. Duhoux⁷, J.-L. Canon⁸, H. Denys⁹, F. Coussy¹⁰, C. Chakiba¹¹, B. Pistilli¹², M. Piccart³, M. Ignatiadis³, P. Aftimos³, ¹ Brussels, BE, ²Insitut Jules Bordet, Brussels, BE, ³Institute Jules Bordet, Brussels, BE, ⁴University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵CHU UCL Namur Sainte-Elisabeth, Namur, BE, ⁶UZ Brussel, Brussels, BE, ⁷Cliniques universitaires Saint-Luc, Brussels, BE, ⁸Grand Hôpital de Charleroi, Charleroi, BE, ⁹UZ Gent, Gent, BE, ¹⁰Institut Curie, Paris Cedex, FR, ¹¹Institut Bergonié, Bordeaux, FR, ¹²Institut Gustave Roussy, Villejuif, FR

09:00 - 09:00 **73TiP - SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)**

E. Ciruelos¹, F.J. Salvador Bofill², A. Perello Martorell³, E. Alba Conejo⁴, X. González-Farré⁵, P. Palacios-Ozores⁶, M. Merino⁷, P. Villagrasa⁸, E. Vila Navarro⁸, T. Pascual⁹, A. Prat¹⁰, S. Pernas Simon¹¹, ¹University Hospital 12 De Octubre, Madrid, ES, ²Hospital Universitario Virgen del Rocío, Sevilla, ES, ³Hospital Universitario Son Espases, Palma de Mallorca, ES, ⁴Hospital Universitario Virgen de la Victoria, Málaga, ES, ⁵Hospital General de Catalunya / Institut Oncològic Dr. Rosell / SOLTI Breast Cancer Research

Group, Sant Cugat del Vallés, ES, ⁶CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ⁷Hospital Infanta Sofia, Madrid, ES, ⁸SOLTI Breast Cancer Research Group, Barcelona, ES, ⁹Hospital Clinic y Provincial de Barcelona / SOLTI Breast Cancer Research Group, Barcelona, ES, ¹⁰Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES, ¹¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

- 09:00 - 09:00 **74P - Identification of women at high risk of breast cancer who need supplemental screening**
K. Czene, M. Eriksson, P. Hall, Karolinska Institutet, Stockholm, SE
- 09:00 - 09:00 **75P - Use of low-dose tamoxifen to improve mammographic screening sensitivity in premenopausal women**
M. Eriksson¹, E. Conant², K. Czene¹, P. Hall¹, ¹Karolinska Institutet, Stockholm, SE, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, US
- 09:00 - 09:00 **76P - The clinical survival benefit of postmastectomy radiotherapy patients screened form T1-2N1M0 breast cancer according to tumour size and the number of lymph nodes**
H. Yang¹, M. Chen², L. Hou³, Y. Huang², ¹ Suining, CN, ²Affiliated Suining Central Hospital of Chongqing Medical University, Suining, CN, ³Affiliated Hospital of North Sichuan Medical College, Nanchong, CN
- 09:00 - 09:00 **77P - The cost effectiveness and cosmetic outcome of vacuum assisted excision compared to surgical excision for the treatment of benign and high-risk lesions**
E. Van De Voort¹, G.M. Struik², C. Verhoef³, T. Klem⁴, ¹ Rotterdam, NL, ²Reinier de Graaf Gasthuis, Delft, NL, ³Erasmus MC - University Medical Center, Rotterdam, NL, ⁴Franciscus Gasthuis en Vlietland, Rotterdam, NL
- 09:00 - 09:00 **78P - A dosimetric study of the non-intended irradiation to the internal mammary lymph nodes during locoregional radiotherapy to the breast**
H. Yassen¹, A. Ismail², A.M. Amin Darwish³, A. Munir⁴, M.I. Abouegylah⁴, A. Kandil⁴, ¹ Alexandria, EG, ²Specialized Universal Network of Oncology (SUN), Alexandria, EG, ³University of Alexandria - Faculty of Medicine, Alexandria, EG, ⁴Alexandria Faculty of Medicine, Alexandria, EG
- 09:00 - 09:00 **79P - Targeted intraoperative radiotherapy vs external beam radiotherapy in early-stage breast cancer patients: A systematic review and meta-analysis**
A. Hadisurya¹, C. Chrystelle², F. Tandy², M. Suciningtias², R. Heriyanto², A. Kurniawan³, A. Giselsania⁴, ¹ Tangerang, ID, ²UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ³Faculty of Medicine, Pelita Harapan University, Tangerang, ID, ⁴University of Indonesia - Faculty of Medicine, Jakarta, ID
- 09:00 - 09:00 **80P - Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers**
Y. Rathore¹, J. Shukla², B. Mittal³, G. Singh², K. Gopal⁴, R. Kumar², A. Bal², I. Laroia², T.

Lakhanpal², ¹ Chandigarh, IN, ²PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN, ³Banaras Hindu University, Varanasi, IN, ⁴CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, IN

- 09:00 - 09:00 **81P - Is there a benefit for nodal evaluation as part of the post-lumpectomy imaging study before radiotherapy?**
A.L. Pires¹, A. Laranja², F. Sousa², B. De Castro², S. Sarandão², S. Costa², F. Fernandes², H. Pereira², ¹ Porto, PT, ²Instituto Portugues de Oncologia - Porto, Porto, PT
- 09:00 - 09:00 **82P - Predicting invasive disease and lymph node involvement in patients with preoperative diagnosis of ductal carcinoma in situ**
A. Tondare¹, F. Irakleidis², J. Timbres³, H. Hamed², A. Kothari², ¹ London, GB, ²Guy's and St. Thomas' Hospital NHS Trust, London, GB, ³King's College, London, GB
- 09:00 - 09:00 **83P - Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study)**
A. Conversano¹, M. Abbaci², M. Karim², M.C. Mathieu², F. De Leeuw², S. Michiels³, C. Laplace-Builhé², C. Mazouni⁴, ¹ Villejuif, FR, ²Gustave Roussy -, Villejuif, FR, ³Gustave Roussy, Villejuif, FR, ⁴Institut Gustave Roussy, Villejuif, FR
- 09:00 - 09:00 **84P - Prospective comparative study of dosimetric parameters and acute radiation toxicity of 3-dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) in post mastectomy carcinoma breast patients**
P. Inampudi¹, R. Seam², L. Pandey², D. Malik², A. Pandey², A. Anjali², A. Hakim², R. Mahajan², S. Sharma², ¹ Ambala, IN, ²Maharshi Markandeshwar Institute of Medical Sciences and Research, Ambala, IN
- 09:00 - 09:00 **85P - Hypofractionated radiotherapy for breast cancer: Does obesity increase the skin toxicity?**
B.A. Raouia¹, M. Bohli², D. Aissaoui², J. Yahiaoui², A. Hamdoun², L. Kochbati², ¹ Ariana, TN, ²Abderrahman Mami Hospital, Ariana, TN
- 09:00 - 09:00 **86P - The impact of the introduction of vacuum assisted excision on clinical management and outcomes of benign and high-risk lesions**
E. Van De Voort¹, G.M. Struik², E. Birnie³, R. Sinke³, M. Macco³, K. Verhoef⁴, T. Klem³, ¹ Rotterdam, NL, ²Reinier de Graaf Gasthuis, Delft, NL, ³Franciscus Gasthuis en Vlietland, Rotterdam, NL, ⁴Erasmus MC - University Medical Center, Rotterdam, NL
- 09:00 - 09:00 **87P - Epigenetics of the epigenetics: Impact of Let-7a expression restoration in CD8⁺ cells of HER2⁺ breast cancer patients**
T. Monier¹, A. Samir², A. El Khodiry², R. Abdel Tawab³, H. El Tayebi², ¹ New Cairo, EG, ²GUC - German University in Cairo, New Cairo, EG, ³Ain Shams University, Cairo, EG
- 09:00 - 09:00 **88P - CXCR2 small molecule antagonists: A novel approach to enhance the effect of PDL-1 inhibitors in triple-negative breast cancer**

A. Ghallab¹, R. Abdel Tawab², H. El Tayebi³, ¹ New Cairo, EG, ²Ain Shams University, Cairo, EG, ³GUC - German University in Cairo, New Cairo, EG

- 09:00 - 09:00 **89P - High expression of miR-18a drives immunosuppressive activity in ER-positive breast cancer**
M. Nair¹, S. Vp², J. Prabhu¹, T. Sridhar¹, ¹St Johns Research Institute, Bangalore, IN, ²St. John's Research Institute, Bangalore, IN
- 09:00 - 09:00 **90TiP - Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial**
V. Geurts¹, L. Voorwerk², K. Sikorska³, M. Van Dongen⁴, I. Kemper⁴, I. Mandjes³, J. Haanen⁴, G. Sonke⁴, M. Kok⁵, ¹ Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴NKI-AVL - Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁵Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 09:00 - 09:00 **97P - Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience**
V. Aggelis¹, P. Mcfarlane², N. Cunningham², S. Gennatas², S. Johnston², A. Okines¹, S. Mcgrath², ¹ London, GB, ²The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
- 09:00 - 09:00 **98P - Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC)**
V. Mueller¹, O. Hoffmann², A. Grafe³, O. Tomé⁴, W. Fett⁵, H.-R. Bruch⁶, A.-K. Sommer⁷, A. Schneeweiss⁸, ¹UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ²Universitätsklinikum Essen, Essen, DE, ³Praxis Dr Grafe/Brustzentrum der Frauenklinik, Su"ndharz-Klinikum Nordhausen gGmbH, Nordhausen, DE, ⁴St. Vincentius-Kliniken gAG, Karlsruhe, DE, ⁵Onkologische Praxis, Wuppertal, DE, ⁶Schwerpunktpraxis Bonn, Bonn, DE, ⁷Roche Pharma AG, Grenzach-Wyhlen, DE, ⁸Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE
- 09:00 - 09:00 **99P - Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome**
B. Kingston¹, R. Cutts², M. Beaney², G. Walsh-Crestani², S. Hrebien², L. Kilburn³, S. Kernaghan³, L. Moretti³, K. Wilkinson³, I. Macpherson⁴, R. Baird⁵, R. Roylance⁶, J. Reis-Filho⁷, M. Hubank⁸, I. Faull⁹, K. Banks⁹, I. Garcia-Murillas², J. Bliss³, A. Ring⁸, N. Turner⁸, ¹ London, GB, ²The Institute of Cancer Research, London, London, GB, ³ICR - Institute of Cancer Research, London, GB, ⁴BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁵Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ⁶University College London Hospitals NHS Foundation Trust, London, GB, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁹Guardant Health, Inc., Redwood City, US
- 09:00 - 09:00 **100P - Efficacy of enobosarm, a selective androgen receptor (AR) targeting**

agent, in patients with metastatic AR⁺/ER⁺ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study

C. Palmieri¹, H. Linden², S. Birrell³, E. Lim⁴, L. Schwartzberg⁵, H. Rugo⁶, P. Cobb⁷, K. Jain⁸, C. Vogel⁹, J. O'Shaughnessy¹⁰, S. Johnston¹¹, R. Getzenberg¹², K.G. Barnette¹², M. Steiner¹², A. Brufsky¹³, B. Overmoyer¹⁴, ¹ Liverpool, GB, ²University of Washington Seattle Cancer Care Alliance, Seattle, US, ³Wellend Health/Burside Hospital, Toorak Gardens, AU, ⁴St Vincent's Hospital and Garvan Institute of Medical Research, Sydney, AU, ⁵West Cancer Center, Germantown, US, ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁷Cancer Centers of Montana, Billings, US, ⁸Ashland Bellefonte Cancer Center, Ashland, US, ⁹University of Miami, Miami, US, ¹⁰Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹¹The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ¹²Veru Inc, Miami, US, ¹³Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, ¹⁴Dana Farber Cancer Institute, Boston, US

09:00 - 09:00 **101P - E-cadherin inactivation by Trop-2 drives EMT-less metastatic relapse in triple-negative breast cancer**

S. Alberti¹, E. Guerra², R. Lattanzio², M. Ceci², K. Boujnah³, V. Relli², V. Garbo³, A. Moschella³, D. Altomare⁴, R. Depalo⁴, M. Trerotola², ¹ Messina, IT, ²University of Chieti, Chieti Scalo, IT, ³AOU Policlinico G. Martino - Università di Messina, Messina, IT, ⁴University of Bari, Bari, IT

09:00 - 09:00 **102P - Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database**

M. Carausu¹, M. Carton², A. Darlix³, D. Pasquier⁴, M. Leheurteur⁵, M. Debled⁶, M.-A. Mouret-Reynier⁷, A. Gonçalves⁸, F. Dalenc⁹, B. Verret¹⁰, M. Campone¹¹, J.-M. Ferrero¹², C. Levy¹³, J.-D. Fumet¹⁴, C. Lefeuvre-Plesse¹⁵, T. Petit¹⁶, C. Jouannaud¹⁷, L. Larrouquere¹⁸, M. Chevrot¹⁹, L. Cabel²⁰, ¹ Saint-Cloud/Paris, FR, ²Institut Curie, Saint-Cloud, FR, ³ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁴Centre Oscar Lambret, Lille, FR, ⁵Centre Henri Becquerel, Rouen, FR, ⁶Institut Bergonié, Bordeaux, FR, ⁷Centre Jean-Perrin, Clermont Ferrand, FR, ⁸Institute Paoli-Calmettes, Marseille, FR, ⁹Institut Claudius Regaud - IUCT Oncopole, Toulouse, FR, ¹⁰Institut Gustave Roussy, Villejuif, FR, ¹¹Institut de Cancérologie de l'Ouest - Site de Nantes -Centre René Gauducheau, SAINT-HERBLAIN, FR, ¹²Centre Antoine Lacassagne, Nice, FR, ¹³Centre Francois Baclesse, Caen, FR, ¹⁴Centre Georges-François Leclerc, Dijon, FR, ¹⁵Centre Eugene Marquis, Rennes, FR, ¹⁶Centre Paul Strauss, Strasbourg, FR, ¹⁷Institut de Cancérologie Jean-Godinot, Reims, FR, ¹⁸Centre Léon Bérard, Lyon, FR, ¹⁹Unicancer, Paris, FR, ²⁰Institut Curie, Saint-Cloud/Paris, FR

09:00 - 09:00 **103P - Long-term results and bone-protective effect of everolimus added to letrozole and ovarian function suppression for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated analysis of the LEO study**

H. Jeong¹, J.H. Jeong¹, J.E. Kim², J.-H. Ahn², K.H. Jung², S.-J. Koh³, J. Cheon³, J.H. Sohn⁴, G.M. Kim⁴, K.S. Lee⁵, S.H. Sim⁵, I.H. Park⁶, S.-B. Kim⁷, ¹Asan Medical Center, Seoul, US, ²Asan Medical Center, Seoul, KR, ³Ulsan University Hospital, Ulsan, KR, ⁴Severance Hospital, Seoul, KR, ⁵National Cancer Center, Goyang, KR, ⁶Korea University Guro

Hospital, Seoul, KR, ⁷Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

- 09:00 - 09:00 **104P - Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3)**
J. Huober¹, E.-M. Grischke², S. Guiu³, N. Quenel Tueux⁴, N. Chouaki⁵, C. Stoffregen⁶, A. Korfel⁶, F. Lerebours⁷, ¹University Hospital Ulm, Ulm, DE, ²Universitätsklinikum Tübingen, Tuebingen, DE, ³Institut de Recherche en Cancérologie de Montpellier, Institut National de la Santé et de la Recherche Médicale, University of Montpellier, Montpellier, Cedex, FR, ⁴Institut Bergonié Comprehensive Cancer Center, Bordeaux, FR, ⁵Eli Lilly and Company, Fegersheim, FR, ⁶Lilly Deutschland GmbH, Bad Homburg vor der Hoehe, DE, ⁷Hôpital René Huguenin - Institut Curie, St. Cloud, FR
- 09:00 - 09:00 **105P - A comparative study of cisplatin plus adriamycin compared with cyclophosphamide plus adriamycin in patients with untreated metastatic triple-negative breast cancer (TNBC)**
S. Yagub¹, M. Khokhar², A. Zafar³, A.W. Goraya⁴, Z.A.K. Niazi³, S. Ishaq², ¹ Lahore, PK, ²King Edward Medical University, Lahore, PK, ³Hameed Latif Hospital, Lahore, PK, ⁴Mayo Hospital, Lahore, PK
- 09:00 - 09:00 **106P - Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR⁺/HER2⁻) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study**
J. Blum¹, C. Dicristo², D. Gordon³, M. Karuturi⁴, D. Oubre⁵, E. Jepsen⁶, J. Cuevas⁷, S. Lakhanpal⁸, Z. Zhang⁹, M. Drucker¹⁰, Y. Wang², D. Tripathy¹¹, ¹ Dallas, US, ²Pfizer Inc, New York, US, ³Munson Medical Center, Traverse City, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵Ponchartrain Cancer Center, Hammond, US, ⁶Novant Health, Winston-Salem, US, ⁷St. Louis Cancer Care, St. Louis, US, ⁸St Vincent's Birmingham, Birmingham, US, ⁹Pfizer Inc, La Jolla, US, ¹⁰ICON plc, San Francisco, US, ¹¹The University of Texas M. D. Anderson Cancer Center, Houston, US
- 09:00 - 09:00 **107P - CDK4/6i adjustment & tumour response in the COVID-19 era**
Z. Tippu¹, C. Ryan², C. Harper-Wynne², ¹ Maidstone, GB, ²Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB
- 09:00 - 09:00 **108P - Epigenetic regulation of the putative breast cancer metastasis suppressor gene SCN4B**
L. Hilgers¹, A. Hartmann², P.A. Fasching³, S. Villwock⁴, L. Moll⁴, S. Roger⁵, R. Knüchel-Clarke⁴, F. Steib⁴, E. Dahl⁴, ¹ Aachen, DE, ²Universitätsklinikum Erlangen, Erlangen, DE, ³University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nurembergen, Erlangen, DE, ⁴Universitätsklinikum Aachen, Aachen, DE, ⁵Université de Tours, Tours, FR
- 09:00 - 09:00 **109P - Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR⁺/HER2⁻) advanced breast cancer (ABC)**

J.C. Laguna Montes¹, F. Brasó-Maristany², T. Pascual³, A. Rodriguez Hernandez¹, N. Chic¹, F. Schettini², E. Sanfeliu Torres¹, B. Gonzalez-Farre¹, D. Martínez², P. Galván², V. Díez-Guardia², B. Adamo⁴, M. Vidal⁴, M.C. Guillén¹, R. Moreno⁵, A. Prat⁶, M. Muñoz⁴, O. Martínez Saez¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ³SOLTI Breast Cancer Research Group, bcn, ES, ⁴Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, ⁵Hospital Clinic of Barcelona, Barcelona, ES, ⁶Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES

09:00 - 09:00 **110P - Adenoid cystic carcinoma of the breast: A case series of 17 patients and literature review**

B. Mery¹, S. Witmeyer², O. Tredan², T. Bachelot², ¹ Lyon, FR, ²Centre Léon Bérard, Lyon, FR

09:00 - 09:00 **111P - Real-world outcomes of patients with breast cancer liver metastases treated with transarterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study**

D. Arnold¹, T. Balli², R. Cianni³, B. Peynircioglu⁴, T. Pfammatter⁵, N. De Jong⁶, T. Helmberger⁷, ¹ Hamburg, DE, ²Cukurova University, Adana, TR, ³S. Camillo Hospital, Rome, IT, ⁴Hacettepe University, Ankara, TR, ⁵Universitätsspital Zürich, Zürich, CH, ⁶CIRSE - Cardiovascular and Interventional Radiological Society of Europe, Vienna, AT, ⁷Klinikum Bogenhausen, Munich, DE

09:00 - 09:00 **112P - Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study**

C. Boman¹, L. Edman Kessler², J. Bergh², A. Matikas², T. Foukakis², ¹ Solna, SE, ²Karolinska Institutet - Bioclinicum, Solna, SE

09:00 - 09:00 **113P - Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie's database**

C. Chalumeau¹, J.-Y. Pierga², G. Pierron², S. Ballet², S. Nasr², A. Vincent-Salomon², P. Vuagnat³, A. Bellesoeur², M. Carton⁴, F.C. Bidard², F. Lerebours⁵, ¹ Saint cloud, FR, ²Institut Curie, Paris, FR, ³Institut Curie, Saint cloud, FR, ⁴Institut Curie, Saint-Cloud, FR, ⁵Hôpital René Huguenin - Institut Curie, St. Cloud, FR

09:00 - 09:00 **114P - Dose modifications of ribociclib and endocrine therapy for treatment of ER⁺; HER2- metastatic breast cancer**

K. Kristensen¹, A. Jensen², A. Kodahl³, T. Berg⁴, I.M. Thomsen⁴, ¹ Aarhus N, DK, ²Aarhus University Hospital, Aarhus N, DK, ³Odense University Hospital, Odense, DK, ⁴Copenhagen University Hospital, Copenhagen, DK

09:00 - 09:00 **115P - Palbociclib-letrozole in advanced breast cancer: A real world review from a regional cancer centre in the United Kingdom**

S. Bose¹, V. Kuriakose², ¹ Wolverhampton, GB, ²NEW CROSS HOSPITAL, Wolverhampton, GB

- 09:00 - 09:00 **116P - Real-world treatment patterns and clinical effectiveness of eribulin in HR⁺/HER2- metastatic breast cancer patients in the United States**
S. Mougalian¹, J. Zhang², J. Kish³, M. Zettler³, B. Feinberg³, ¹ New Haven, US, ²Eisai Inc., Woodcliff Lake, US, ³Cardinal Health Specialty Solutions, Dublin, US
- 09:00 - 09:00 **117P - Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors**
P. Rottier¹, A. Da Silva², C. Levy², D. Allouache², A. Johnson², I. Hrab², A. Faveyrial², K. Gunzer², C. Segura Djezzer², A. Morel², M. Villemin², C. Boscher², L. Boismoreau², F. Cherifi², J. Lequesne², G. Emile², ¹ Caen, FR, ²Centre Francois Baclesse, Caen, FR
- 09:00 - 09:00 **118P - Determinants of timing to metastasis in breast cancer patients in Albania**
F. Kraja¹, A. Hoti², I. Akshija², E. Tola³, A. Kristo², O. Shazi², H. Nina², ¹ Tirana, AL, ²Tirana University Hospital Center "Mother Teresa", Tirana, AL, ³Fier Regional Hospital, Fier, AL
- 09:00 - 09:00 **119P - Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence**
J.H. Jeong¹, H. Jeong¹, J.E. Kim², J.-H. Ahn², K.H. Jung², S.-B. Kim³, ¹Asan Medical Center, Seoul, US, ²Asan Medical Center, Seoul, KR, ³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 09:00 - 09:00 **120P - Prognostic significance of SAMHD1 expression in breast cancer**
M. Margeli Vila¹, L. Gutierrez², E. Riveira², V. Quiroga Garcia¹, M. Romeo³, B. Cirauqui³, I. Teruel³, A. Pous³, A. Ferrando³, A. Martinez-Cardús⁴, E. Ballana², ¹ Badalona, ES, ²IRSICAIXA, Badalona, ES, ³ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol); B-ARGO (Badalona Applied Research Group), Badalona, ES, ⁴Badalona·Applied Research Group in Oncology (B·ARGO), Badalona, ES
- 09:00 - 09:00 **121P - Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study**
C. Saavedra Serrano¹, B. Pérez Mies², M. Gion Cortes², A. Cortes Salgado², M. Fernández Abad², N. Martínez-Jañez³, M. Soriano², E.M. Guerra², E. Lopez Miranda², ¹ Madrid, ES, ²Hospital Universitario Ramon y Cajal, Madrid, ES, ³Hospital Universitario Ramón y Cajal. GEICAM Breast Cancer Group, Madrid, ES
- 09:00 - 09:00 **122P - Abemaciclib in HR⁺/HER2- metastatic breast cancer: A real-world experience**
M. Bottosso¹, T. Giarratano², C. Barbieri³, A. Menichetti², E. Cumerlato³, F. Miglietta³, E. Genovesi³, O. Amato³, M.V. Dieci², G. Griguolo³, V. Guarneri⁴, ¹ Padova, IT, ²IIOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³University of Padova, Padova, IT, ⁴Istituto Oncologico Veneto IRCCS, Padova, IT
- 09:00 - 09:00 **123P - Clinical and pathological characteristics of male breast cancer at the Institute for Oncology including first-line treatment in hormone receptor**

positive tumours

K. Serovic¹, M. Jevric², S. Susnjar³, I. Bozovic Spasojevic³, ¹ Belgrade, RS, ²Institute of oncology and radiology, Belgrade, RS, ³Institute for Oncology and Radiology of Serbia, Belgrade, RS

09:00 - 09:00

124P - Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

M. Sendur¹, B. Cakar², M. Hizal³, E. Eraslan⁴, S. Aksoy⁵, S. Paydas⁶, N. Demir⁷, F. Sen⁸, G. Bulut⁹, K. Oruc¹⁰, B. Oyan Uluc¹¹, N. Ozdemir¹², A. Sakin¹³, D. Erdem¹⁴, M. Özkan¹⁵, U. Disel¹⁶, F. Ekinici¹⁷, I. Okten¹⁸, L. Ozer¹¹, E. Gokmen¹⁹, ¹ Ankara, TR, ²Ege University Faculty of Medicine, Izmir, TR, ³Ankara City Hospital, Ankara, TR, ⁴Abdurrahman Yurtaslan Ankara Onkology Education and Research Hospital, Ankara, TR, ⁵Hacettepe University Faculty of Medicine, Ankara, TR, ⁶Cukurova University Faculty of Medicine, Adana, TR, ⁷Medicana Sivas Hospital, Sivas, TR, ⁸Avrasya Hospital, Istanbul, TR, ⁹Defne Hospital, Hatay, TR, ¹⁰Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, TR, ¹¹Acibadem University Faculty of Medicine, Istanbul, TR, ¹²Gazi University Faculty of Medicine, Ankara, TR, ¹³Yuzuncu Yil University Faculty of Medicine, Van, TR, ¹⁴Bahcesehir University Faculty of Health Sciences, Istanbul, TR, ¹⁵Erciyes University Medical Faculty M.Kemal Dedeman, Oncology Hospital, Kayseri, TR, ¹⁶Acibadem Adana Hastanesi, Adana, TR, ¹⁷MCBU-Manisa Celal Bayar University - Faculty of Medicine, Manisa, TR, ¹⁸S.B. Istanbul Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR, ¹⁹Ege University Medical School, Izmir, TR

09:00 - 09:00

125TiP - SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumours with HER2 alterations: HER2-mutated breast cancer cohort

A. Okines¹, V. Kang², L.N. Walker³, P. Pohlmann⁴, ¹ London, GB, ²Seagen Inv., Bothell, US, ³Seagen Inc, Seattle, US, ⁴Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, US

09:00 - 09:00

126TiP - HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2-positive breast cancer

S. Hurvitz¹, N. Harbeck², L. Vahdat³, A. Wolff⁴, S. Tolaney⁵, S. Loi⁶, N. Masuda⁷, J. O'Shaughnessy⁸, D. Xie⁹, L.N. Walker¹⁰, E. Rustia⁹, V. Borges¹¹, ¹UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴Johns Hopkins University, Baltimore, US, ⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷National Hospital Organization Osaka National Hospital, Osaka, JP, ⁸Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁹Seagen Inc, Bothell, US, ¹⁰Seagen Inc, Seattle, US, ¹¹University of Colorado Cancer Center, Lone Tree, US

09:00 - 09:00

127TiP - Phase II, open-label study to evaluate the safety and efficacy of praluzatamab rvtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2-; BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC)

K. Miller¹, L. Emens², S. Tolaney³, S. Hurvitz⁴, E. Hamilton⁵, V. Paton⁶, A. Hannah⁶, V.

Boni⁷, ¹ Indianapolis, US, ²University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, US, ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ⁴UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁵Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ⁶CytomX Therapeutics, South San Francisco, US, ⁷South Texas Accelerated Research Therapeutics (START) Madrid, Centro Integral Oncologico Clara Campal, Madrid, ES

09:00 - 09:00

128TiP - HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases

E. Hamilton¹, J. Ramos², W. Feng³, I. Krop⁴, ¹Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ²Seagen Inc., Seattle, US, ³Seagen, Bothell, US, ⁴Dana-Farber Cancer Institute, Boston, US

09:00 - 09:00

132P - The psychological impact of the COVID-19 pandemic on patients with early breast cancer

S. Almeida¹, D. Frاسquilho², G. Cotovio³, F. Viana³, B. Sousa², J. Oliveira³, J. Mattson⁴, C. Marzorati⁵, I. Roziner⁶, E. Karademas⁷, E. Kolokotroni⁸, G. Stamatakos⁸, K. Mazzocco⁹, R. Pat-Horenczyk¹⁰, P. Poikonen-Saksela⁴, F. Cardoso², A. Oliveira-Maia³, ¹ Lisbon, PT, ²Champalimaud Foundation Cancer Center, Lisbon, PT, ³Champalimaud Clinical and Research Centre - Champalimaud Centre for the Unknown, Lisbon, PT, ⁴Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FI, ⁵European Institute of Oncology, Milan, IT, ⁶Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IL, ⁷FORTH-ICS, Heraklion, GR, ⁸National Technical University of Athens, Athens, GR, ⁹IEO - Istituto Europeo di Oncologia, Milan, IT, ¹⁰The Hebrew University of Jerusalem, Tel Aviv, IL

09:00 - 09:00

133P - Breast cancer in young women (BCYW): Different entity or different needs?

J. Sanchez, B. Nunez Garcia, M. Mendez Garcia, M. Blanco Clemente, A. Morito Aguilar, B. De La Puente Orteu, C. De La Fuente, D. Suárez, M. Provencio Pulla, B. Cantos Sanchez De Ibarquen, Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES

09:00 - 09:00

134P_PR - Towards tailored follow-up care for breast cancer survivors: Cluster analyses based on symptom burden

K. De Ligt¹, B. De Rooij², I. Walraven³, M. Heins⁴, S. Siesling², J. Korevaar⁴, L. Van De Poll-Franse⁵, ¹ Amsterdam, NL, ²Netherlands Comprehensive Cancer Organization, Utrecht, NL, ³Radboudumc, Nijmegen, NL, ⁴Netherlands Institute of Health Services Research, Utrecht, NL, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:00 - 09:00

135P - Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy

A. Kurniawan¹, D. Halim¹, C. Jodhinata¹, P. Lukito¹, R. Hatma², A. Adisasmita², S. Panigoro³, N. Sutandyo³, T. Tamin³, F. Witjaksono³, R. Sumantri⁴, D. Rivami¹, ¹Faculty of Medicine, Pelita Harapan University, Tangerang, ID, ²Faculty of Public Health, Universitas Indonesia, Depok, ID, ³Faculty of Medicine, Universitas Indonesia, Jakarta, ID, ⁴Faculty of Medicine, Padjadjaran University, Bandung, ID

- 09:00 - 09:00 **136P - The incidence and prognostic impact of obesity in young Egyptian breast cancer patients**
A. Athman Omar¹, A.M. Amin Darwish², ¹ Alexandria, EG, ²University of Alexandria - Faculty of Medicine, Alexandria, EG
- 09:00 - 09:00 **137P - Survivorship care plan for breast cancer patients: An intensive follow-up is still useless?**
G. Cortesi, L. Moscetti, M. Barbolini, C. Nasso, C. Isca, R. D'Onofrio, M. Dominici, C. Omarini, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT
- 09:00 - 09:00 **138P - Absenteeism at work in breast cancer patients undergoing therapy**
M. Nesrine¹, Y. Berrazega¹, H. Rachdi¹, I. Harhira¹, N. Daoud¹, H. Boussen², ¹Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, ²Abderrahmen Mami Hospital, Ariana, TN
- 09:00 - 09:00 **139P - Association of baseline neutrophil-lymphocyte and platelet-lymphocyte ratios with disease progression in high-risk breast cancer patients**
R. Cahyono¹, S.L. Anwar², H.Y. Budiman², T. Aryandono², W.A. Harahap³, ¹ Yogyakarta, ID, ²Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID, ³Faculty of Medicine, Andalas University, Padang, ID
- 09:00 - 09:00 **140P - How breast cancer recurrences are found? A real-world, prospective cohort study**
S. Myller¹, A. Jukkola², A. Jääskeläinen³, N. Roininen³, P. Karihtala⁴, ¹ Oulu, FI, ²Tampere University Hospital and Tampere University, Tampere, FI, ³Oulu University Hospital and University of Oulu, Oulu, FI, ⁴Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, FI
- 09:00 - 09:00 **141P - Cognitive impairment among breast cancer patients receiving endocrine treatment: A comparative study between aromatase inhibitors and tamoxifen**
I. Ben Abdallah¹, H. Rachdi², M. Nesrine², Y. Berrazega², H. El Benna², N. Daoud², S. Laabidi³, H. Boussen⁴, ¹ Tunis, TN, ²Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, ³Hopital Abderrahmen Mami de Pneumo-Phistologie, Ariana, TN, ⁴Abderrahmen Mami Hospital, Ariana, TN
- 09:00 - 09:00 **142P - Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER⁺) early breast cancer (EBC): An observational single centre study**
C. Harper-Wynne¹, R. Burcombe², ¹Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB, ²Kent Oncology Centre, QQ, GB
- 09:00 - 09:00 **143P - Fertility rates in young breast cancer patients (YBCP) and evolution: A new challenge**
M. Mendez Garcia, B. Nunez Garcia, M. Blanco Clemente, J. Sanchez, S. Herrero, V. Engels, G. Visedo, M. Martinez Cutillas, M. Provencio Pulla, B. Cantos Sanchez De Ibarguen, Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES

- 09:00 - 09:00 **144P - Cognitive complaints among Tunisian breast cancer patients receiving adjuvant aromatase-inhibitors**
I. Ben Abdallah¹, H. Rachdi², D. Dhib³, M. Nesrine², Y. Berrazega², H. El Benna², N. Daoud², S. Laabidi⁴, H. Boussen⁵, ¹ Tunis, TN, ²Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, ³University of Tunis El Manar - Faculty of Medicine, Tunis, TN, ⁴Hopital Abderrahmane Mami de Pneumophistologie, Ariana, TN, ⁵Abderrahmen Mami Hospital, Ariana, TN
- 09:00 - 09:00 **145P - The potential benefits of internet-based cognitive behavioural therapy for improving psychosocial aspects, sexual functioning, and treatment-induced menopausal symptoms among breast cancer survivors: Systematic review and meta-analysis**
B.P. Putra¹, F.N. Putra², ¹ Blitar, ID, ²Universitas Airlangga, Surabaya, ID
- 09:00 - 09:00 **146P - Impact of breast cancer treatment on sexual health in pre-menopausal women**
S. Garg¹, L. Enny², K. Singh², P. Ramakant², A. Mishra², ¹ Lucknow, IN, ²KGMU - King George's Medical University, Lucknow, IN
- 09:00 - 09:00 **147P - When a single G-CSF administration is better than longer duration: Example in patients treated by eribulin**
A. Schmitt¹, M. Reda², P. Macaire², H. Bellio², L. Uwer³, S.M. Ilie², V. Lorgis⁴, A. Hennequin², S. Ladoire², E. Rederstorff², P. Fumoleau⁵, N. Isambert², N. Bonnin⁶, B. You⁶, G. Freyer⁷, I. Desmoulins², ¹ Dijon, FR, ²Centre Georges-François Leclerc (Dijon), Dijon, FR, ³Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁴Polyclinique Du Parc Drevon, Dijon, FR, ⁵Institut Curie, Paris, FR, ⁶Ch Lyon Sud, Pierre Benite, FR, ⁷Lyon Sud Hospital Center - HCL, Pierre Benite, FR
- 09:00 - 09:00 **148P - Breast cancer as second primary malignancy in cancer survivors: Experience from a Tertiary Cancer Center in India**
R. Joseph P¹, A. T M², G. Narayanan², S. Nair², ¹ Thiruvananthapuram, IN, ²Regional Cancer Centre, Thiruvananthapuram, IN
- 09:00 - 09:00 **149P - Restricted mean survival time (RMST): A new tool for time to event analysis in young breast cancer patients (YBCP)**
J. Sanchez, M. Mendez Garcia, B. Nunez Garcia, M. Blanco Clemente, J. Mucientes, M. López Valcárcel, R. Aguado, A. Royuela, M. Provencio Pulla, B. Cantos Sanchez De Ibarguen, Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES
- 09:00 - 09:00 **150P - Expanding the potential benefits of cognitive behavioural therapy for insomnia in improving psychological functioning and quality of life among breast cancer survivors with insomnia: A meta-analysis of randomized controlled trials**
B.P. Putra¹, F.N. Putra², ¹ Blitar, ID, ²Universitas Airlangga, Surabaya, ID
- 09:00 - 09:00 **151P - Impact of germline BRCA (gBRCA) mutation (m) status on clinical**

characteristics and patterns of care among women with early breast cancer (eBC): An analysis of the observational prospective CANTO cohort

A. Bertaut¹, J. Blanc², B. Pistilli³, A. Dhaini Merimeche⁴, O. Rigal⁵, C. Coutant (Coutant)⁶, M. Fournier⁷, C.C. Jouannaud (Jouannaud)⁸, P. Soulie⁹, F. Lerebours¹⁰, P. Cottu¹¹, O. Tredan¹², L. Vanlemmens¹³, C. Levy¹⁴, M.-A. Mouret-Reynier¹⁵, M. Campone¹⁶, A.-L. Martin¹⁷, A. Jacquet Jacquet¹⁷, N. Briot², I. Vaz-Luis³, ¹ Dijon, FR, ²Centre Georges-François Leclerc, Dijon, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Centre Alexis Vautrin, NANCY, FR, ⁵Centre Henri Becquerel, ROUEN, FR, ⁶Centre Georges Francois Leclerc, Dijon, FR, ⁷Institut Bergonié, BORDEAUX, FR, ⁸Institut Jean Godinot, Reims, FR, ⁹Institut de Cancérologie de L'ouest -Paul Papin, ANGERS, FR, ¹⁰Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ¹¹Institut Curie, Paris, FR, ¹²Centre Léon Bérard, Lyon, FR, ¹³Centre Oscar Lambret, Lille, FR, ¹⁴Centre Francois Baclesse, Caen, FR, ¹⁵Centre Jean-Perrin, Clermont Ferrand, FR, ¹⁶Institut de Cancérologie de l'Ouest - Site de Nantes -Centre René Gauducheau, SAINT-HERBLAIN, FR, ¹⁷Unicancer, Paris, FR

09:00 - 09:00 **152P - Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland**

R. Mclaughlin¹, D. O'Reilly², C. Ronayne², E. Barrett³, R. Kalachand³, A.M. De Frein⁴, B. Macanovic², R. Connolly⁵, D. Power², R. Bambury², S. Reilly², D. Collins², ¹ Limerick, IE, ²Cork University Hospital, Cork, IE, ³University Hospital Limerick, Limerick, IE, ⁴National Cancer Control Programme, Dublin, IE, ⁵University College Cork, Cork, IE

09:00 - 09:00 **153P - Prevalence and survival of stage IV male breast cancer: A SEER database analysis**

P. Miguel-Semedo¹, C. Costa Lopes Pinto², L.A. Marques Da Costa², A. Ferreira³, ¹ Lisbon, PT, ²Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, PT, ³Champalimaud Foundation, Lisbon, PT

09:00 - 09:00 **154P - Impact of COVID-19 on diagnosis and surgical care of patients with breast cancer**

A. L., V. Kumar, P. K, J. Dharmarajan, S. Soman, H. Jayamohanan, A. Vinod, Amrita Institute of Medical Sciences, Kochi/Cochin, IN

09:00 - 09:00 **155P - Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a North Indian tertiary care center**

A. Mittal¹, R. Pramanik², A. Gogia², A. Batra², A. Jha², L. Kumar², S. Deo², S. Bhorival², K. Deb², E. Dhamija², V. Ramprasad², O. Olopade³, ¹ New Delhi, IN, ²AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ³University of Chicago, chicago, US

09:00 - 09:00 **156P - The effectiveness of intraoperative administration of both radioactive isotope and blue dye without pre-surgery gamma imaging in comparison with the conventional technique for sentinel node biopsy**

V. Kumar, A. L, R. Aggarwal, P. Sundaram, Amrita Institute of Medical Sciences, Kochi/Cochin, IN

09:00 - 09:00 **157P - Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021**

M. Lythgoe¹, J. Krell², L. Kenny², A. Khaki³, ¹ London, GB, ²Imperial College London - Hammersmith Hospital, London, GB, ³University of Washington, Seattle, US

09:00 - 09:00 **158P - Obstructive sleep apnea and breast cancer incidence: A systematic review and meta-analysis**

N. Tan¹, B.K.J. Tan¹, Y.H. Teo¹, V. Tan², A. See³, S.T. Toh³, ¹NUS-National University of Singapore, Singapore, SG, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³Singapore General Hospital, Singapore, SG

09:00 - 09:00 **159P - Obesity and oral contraceptives reduce the preventive benefit of breastfeeding against breast cancer in Mexican women**

A. Guerra Cepeda¹, H. Rodriguez Gutierrez², R. Cerda Flores³, O. Solis Coronado⁴, D. Reding Hernandez⁴, J. Gonzalez Guerrero⁴, O. Vidal Gutierrez⁴, D. Perez Ibañez⁴, M. Garza Rodriguez⁴, ¹University Autonomous of Nuevo Leon, Monterrey, MX, ²MONTERREY, MX, ³University Autonomous of Nuevo Leon, MONTERREY, NUEVO LEON, MX, ⁴University Autonomous of Nuevo Leon, MONTERREY, MX

09:00 - 09:00 **160P - Distribution of mammographic density and its relationship to age in men**

H. Lee, Philadelphia, US

09:00 - 09:00 **161P - Impact of HIV infection on mortality rate and overall survival of women with breast cancer in a Haitian Mettere Cancer Clinic**

J.J. Bernard¹, L. Alexis², D.P. Gilbert², V.J. Degennaro², ¹ Port-au-Prince, HT, ²Innovating Health International Cancer Program, Port-au-Prince, HT

09:00 - 09:00 **162P - Unique challenges and outcomes of young breast cancers from a tertiary care cancer centre in India**

J. Bajpai¹, V. Pradeep², R. Nandhana², S. Mohanty², Q. Chougale², M. Engineer², S. Rath², S. Joshi², T. Wadasawala², P. Popat², R. Pathak², S. Gulia², J. Ghosh², P. Bhargava², S. Srinivas², T. Shet², R. Sarin², R. Badwe², S. Gupta², ¹ Mumbai, IN, ²Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN

09:00 - 09:00 **163P - Epidemiological profile of breast cancer in Morocco: First results from the Reference Center for Reproductive Health in Kenitra**

F. Aboulhoda¹, A. Soulaymani², F. Bejja², A. Mokhtari², H. Hami², ¹ Kenitra, MA, ²Faculty of Science, Ibn Tofail University, Kenitra, MA

09:00 - 09:00 **164P - Usefulness of positron emission tomography for determination of axillary metastasis of breast cancer**

G. Pösteki¹, A. Güresin², S. Güler², N. Cantürk², ¹ Izmit, TR, ²Kocaeli University, Kocaeli, TR

09:00 - 09:00 **165P - Comparison of male and female breast cancer in reference hospital in Mexico**

G. Sánchez¹, A. Gutierrez², J.C. Jiménez³, R. Correa⁴, J. Alegria Banos⁵, R. Grajales Alvarez⁴, ¹ Ciudad de Mexico, MX, ²58 Regional Hospital IMSS, Leon, MX, ³National

Autonomous University of Mexico, Ciudad de Mexico, MX, ⁴Hospital de Oncología, Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social, Ciudad de Mexico, MX, ⁵Hospital Medica Sur, Ciudad de Mexico, MX

- 09:00 - 09:00 **166P - Breast cancer at the age of 90 and above**
J. Barinoff¹, K.C.K. Ho², J. Schikschneit², U. St.Hilaire², K. Brandt², M.Y. Vornhecke², ¹ Berlin, DE, ²St. Gertrauden-Krankenhaus, Berlin, DE
- 09:00 - 09:00 **167P - Reproductive factors and hormonal contraceptives in relation with breast cancer histopathology**
A. Malek¹, E. Gusbi², M. Grain³, M. Eddeb³, M. Erzeghi³, H. Ahmed⁴, ¹ Tripoli, LR, ²Biotechnology And research Center, Tripoli, LY, ³Tripoli University Hospital, Tripoli, LY, ⁴Tripoli University, Tripoli, LY
- 09:00 - 09:00 **168P - Danish women favour hypothetical breast cancer screening with harms, but no benefits**
E.-L. Johansen¹, A. Bo², S. Borgquist³, T. Grønberg², I. Kristiansen⁴, L. Scherer⁵, H. Støvring², ¹ Aarhus, DK, ²Aarhus University, Aarhus, DK, ³Aarhus University Hospital, Aarhus, DK, ⁴Oslo University, Oslo, NO, ⁵University of Colorado, Denver, US
- 09:00 - 09:00 **169P - Evaluation of the effectiveness of telephone consultations and the level of satisfaction of patients attending the Unidad Docente Asistencial de Mastología [Mastology Care Teaching Unit] using this method during the COVID health emergency**
N. Camejo¹, C. Castillo², N. Artagaveytia³, D. Amarillo³, F. Vitureira³, F. Rodriguez³, L. Delgado³, ¹ Montevideo, UY, ²Hospital de Clinicas, Montevideo, UY, ³Hospital de Clinicas Dr. Manuel Quintela, Montevideo, UY
- 09:00 - 09:00 **170P - Pattern and prognosis of fatal cardiac events in locoregional and distant stages in female breast cancer patients: SEER- based analysis**
M. Safi¹, D. Trapani², M. Alradhi³, A. Al-Danakh⁴, X. Shan⁵, F. Ping⁴, A. Al-Masni⁶, Y. Jamal⁷, N. Al-Sabai⁷, A. Al-Dhaibani⁵, A. Al-Samawi⁷, M. Al-Sameai⁷, A. Al-Sharabi⁷, J. Liu⁵, ¹ Dalian, CN, ²Istituto Europeo di Oncologia, Milan, IT, ³Second affiliated hospital of Dalian medical university, Dalian city, CN, ⁴The first affiliated hospital of Dalian medical university, Dalian city, CN, ⁵First affiliated hospital of Dalian Medical University, Dalian, CN, ⁶Princess Rahma Pediatric Hospital, Irbid, JO, ⁷Dalian Medical University, Dalian, CN
- 09:00 - 09:00 **171P - Validity and reliability tests of the UNS-CASKQ14 questionnaire about the quality and compliance of breast cancer survivors amid the COVID-19 pandemic**
W. Soewoto¹, M.D. Putra², G. Putra², ¹ Surakarta, ID, ²Medical Faculty of Sebelas Maret University, Surakarta, ID
- 09:00 - 09:00 **172P - Men with breast cancer: Biology and stage at diagnosis in Eastern Europe - Balkan Collaborative Project**
M. Vasileva¹, A. Piciu², N. Polocoser³, A.-A. Kovendi³, Z. Inic⁴, M. Jevric⁴, A. Yordanov⁵, S. Volovat⁶, A. Konsoulova⁷, ¹ Sofia, BG, ²University of Medicine and Pharmacy, Cluj-

Napoca, RO, ³Institute of Oncology, Cluj-Napoca, RO, ⁴Institute of oncology and radiology, Belgrade, RS, ⁵Medical University Pleven, Pleven, BG, ⁶University of Medicine and Pharmacy "Gr.T.Popa", Iasi, RO, ⁷Complex Oncological Center Burgas, Burgas, BG

- 09:00 - 09:00 **173P - Quality indicators of treatment of breast cancer in Bulgaria**
M. Vasileva¹, S. Maslyankov², N. Velikova³, K. Nedev³, I. Georgiev³, E. Chupryna⁴, S. Strashilov⁵, A. Yordanov⁵, ¹ Sofia, BG, ²Alexandrovskia University Hospital, Sofia, BG, ³Acibadem City Clinic, Sofia, BG, ⁴Military Medical Academy, Sofia, BG, ⁵Medical University Pleven, Pleven, BG
- 09:00 - 09:00 **174P - Breast screening at young age: A real need?**
B. Nunez Garcia, J. Sanchez, M. Blanco Clemente, M. Mendez Garcia, M.C. Vega, S. Carmona, B. De La Puente, A. Morito Aguilar, M. Provencio Pulla, B. Cantos Sanchez De Ibarquen, Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES
- 09:00 - 09:00 **175P - Tumour biology in young breast cancer patients (YBCP): A different disease?**
B. Cantos Sanchez De Ibarquen, M. Mendez Garcia, M. Blanco Clemente, B. Nunez Garcia, C. Corbacho, C. Gonzalez Lois, R. Aguado, Y. Garitaonandia, M. Provencio Pulla, J. Sanchez, Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES
- 09:00 - 09:00 **176P - Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre**
K. Balachandran¹, J. Williams², D. Bell², A. Brown², S. Mahmoud², P. Hurhangee², R. Ramakrishnan², S. Cleator², R.C. Coombes³, O. Hatcher², F. Rehman², J. Stebbing³, L. Kenny³, ¹ London, GB, ²Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, GB, ³Imperial College London - Hammersmith Hospital, London, GB
- 09:00 - 09:00 **177P - COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital**
M.C. Guillén¹, E. Núñez-Manchón², X. Bargalló³, B. Adamo⁴, I. Alonso³, M. Mollà³, M. Vidal⁴, G. Oses González³, X. Caparrós³, B. Gonzalez-Farre¹, N. Chic¹, O. Martínez Saez¹, B. Ubeda³, R. Moreno³, I. Cebrecos³, J. Fontdevila Font³, S. Vidal-Sicart³, A. Rodríguez³, A. Prat⁵, M. Muñoz⁴, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Fundació Clínic per la Recerca Biomèdica, Barcelona, ES, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, ⁵Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES
- 09:00 - 09:00 **178P - Imaging for distant metastasis in local and locally advanced breast cancer: Practice and detection rates**
A. Da Silva Oliveira, I. Dunoos, R. Cunha, T. Carvalho, E. Bravo, R. Dinis, Hospital Espírito Santo, EPE - Évora, Évora, PT
- 09:00 - 09:00 **179P - Discordance rates of clinicopathological features in bilateral breast cancer**
A. Aranda-Gutierrez¹, A. Ferrigno², B. Vaca-Cartagena², F. Gonzalez-Mondellini³, A.

Becerril-Gaitán², M. Roman-Zamudio³, M. Acosta-Sandoval³, M. Torres-Leal³, C. Treviño-Alanis³, H. Diaz-Perez², S. Cardona², C. Villarreal-Garza², ¹ San Pedro Garza Garcia, MX, ²Hospital Zambrano Hellion, Tecnológico de Monterrey, San Pedro Garza Garcia, MX, ³Escuela de Medicina y Ciencias de la Salud, Monterrey, MX

09:00 - 13:15 **180P - Factors associated with late-stage diagnosis of breast cancer among Egyptian women**

H. Ismail¹, S. Mokhtar², H. El-Mansy³, ¹ Alexandria, EG, ²The High Institute of Public Health, Alexandria, EG, ³Medical Research Institute, Alexandria, EG

17:30 - 18:30 Type: Industry Satellite Symposia Channel 1
Title: Eisai Europe Ltd

17:30 - 17:50 **TBC**

17:30 - 18:30 Type: Industry Satellite Symposia Channel 1
Title: Eisai Europe Ltd - Halaven (eribulin) 10 years on: What is the role of eribulin in the contemporary management of mBC
 Chair(s): Joyce O'Shaughnessy, US

17:30 - 17:32 **Introduction**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

17:32 - 17:47 **MBC treatment evolution from the past 10 years**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

17:47 - 17:57 **The role of eribulin in the contemporary management of mBC**
S. Ahmed, Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB

17:57 - 18:12 **The importance of clinical experience and RWE**
A. Gennari, Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT

18:12 - 18:15 **Conclusions**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

18:15 - 18:30 **Live Q&A/discussion**
A. Speakers, , CH

17:30 - 18:30	Type: Industry Satellite Symposia Title: MSD - Advanced TNBC: Emerging landscape and treatment options Chair(s): Martine Piccart, BE	Channel 2
----------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------

17:30 - 17:35 **Introduction and objectives**
M. Piccart, Institute Jules Bordet, Brussels, BE

17:35 - 17:45 **Unmet need in advanced TNBC**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

17:45 - 18:00 **Review of recent data with IO + Chemo**
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

18:00 - 18:15 **Overview of biomarker assays in advanced TNBC**
G. Vainer, Hadassah Medical Centre, Jerusalem, IL

18:15 - 18:25 **Patient case study**
A. Speakers, , CH

18:25 - 18:30 **Closing remarks**
M. Piccart, Institute Jules Bordet, Brussels, BE

19:00 - 20:00	Type: Industry Satellite Symposia Title: CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Chair(s): Javier Cortes Castan, ES	Channel 1
19:00 - 19:05	Medical need to improve on standard therapies for HR+/HER2- EBC <u>J. Cortes Castan</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:05 - 19:15	Individualizing therapeutic decision-making for patients with HR+/HER2- EBC <u>J. Cortes Castan</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:15 - 19:30	Adjuvant therapy for patients with HR+/HER2- EBC at high risk of recurrence <u>S. Johnston</u> , The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
19:30 - 19:40	Debating optimal neoadjuvant therapy <u>S. Tolaney</u> , Dana-Farber Cancer Institute, Harvard Medical School, Boston, US	
19:40 - 19:50	Summary, final thoughts and live Q&#38;A <u>A. Speakers</u> , , CH	
19:50 - 19:55	Future considerations on the horizon for HR+/HER2- EBC <u>S. Tolaney</u> , Dana-Farber Cancer Institute, Harvard Medical School, Boston, US	

06.05.2021

17:30 - 18:30 **Type: Industry Satellite Symposia** **Channel**
Title: Pfizer Oncology - Navigating a new clinical reality in advanced **1**
breast cancer: Treatment considerations in the real world
Chair(s): Guy Jerusalem, BE

17:30 - 17:35 **Welcome and introduction**
G. Jerusalem, CHU Liège and Liège University,, Liège, BE

17:35 - 18:00 **From clinical trials to real-world effectiveness: Charting a new standard in HR+/HER2- breast cancer**
D. Patt, University of Texas at Austin, Dell Medical School, LiveStrong Cancer Institutes, Austin, US

18:00 - 18:15 **The route to a new reality: Treatment considerations for gBRCA-mutated aBC**
M. Lux, Paderborn, DE

18:15 - 18:30 **Q&A discussion**
A. Speakers, , CH

19:00 - 20:00	Type: Industry Satellite Symposia Title: Novartis Oncology - What makes the difference in treating HR+, HER2- ABC?	Channel 1
	Chair(s): Stephen Chia, CA	
19:00 - 19:00	Opening remarks <u>S. Chia</u> , BC Cancer Agency - Vancouver, Vancouver, CA	
19:00 - 19:10	OS data with CDK4/6i: What do the data tell us? <u>S. Chia</u> , BC Cancer Agency - Vancouver, Vancouver, CA	
19:10 - 19:20	Treatment decision: How tumor biology can help <u>E. Ciruelos</u> , University Hospital 12 De Octubre, Madrid, ES	
19:20 - 19:30	Discussion <u>A. Speakers</u> , , CH	
19:30 - 19:40	PI3K&#945; inhibitors: Addressing unmet needs through precision medicine in HR+, HER2- ABC - From scientific breakthrough to clinical practice <u>P. Aftimos</u> , Institute Jules Bordet, Brussels, BE	
19:40 - 19:40	PI3K&#945; inhibitors: Addressing unmet needs through precision medicine in HR+, HER2- ABC - From scientific breakthrough to clinical practice <u>E. Ciruelos</u> , University Hospital 12 De Octubre, Madrid, ES	
19:40 - 19:50	Discussion <u>A. Speakers</u> , , CH	
19:50 - 20:00	Live Q&A session <u>A. Speakers</u> , , CH	
20:00 - 20:00	Closing remarks <u>S. Chia</u> , BC Cancer Agency - Vancouver, Vancouver, CA	

20:00 - 21:00 **Type: YO Virtual Lounge Discussions** **Lounge**
Title: How to optimize breast cancer management in older adults? When young meet old
Chair(s): Kevin Punie, BE

20:00 - 21:00 **Mentor**
H. Wildiers, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

21:00 - 21:00 **Mentor**
L. Biganzoli, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT

07.05.2021

11:55 - 12:30	Type: Opening Title: Welcome to the ESMO Breast Cancer Virtual Congress 2021 and Award lecture 2021 Chair(s): Giuseppe Curigliano, IT; Sibylle Loibl, DE; Sung-Bae Kim, KR	Channel 1
11:55 - 11:56	Live welcome <u>S. Loibl</u> , GBG, Neu-Isenburg, DE	
11:56 - 11:59	Prof. J. Baselga commemoration <u>G. Curigliano</u> , European Institute of Oncology, Milan, IT	
11:59 - 12:00	Live welcome <u>S.-B. Kim</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
12:00 - 12:05	Introduction to the ESMO Breast Cancer 2021 Award lecture <u>S. Loibl</u> , GBG, Neu-Isenburg, DE	
12:05 - 12:30	<i>Title to be announced</i> <u>S. Not Yet Confirmed</u> , , CH	

12:45 - 14:00 **Type: Educational session** **Channel 1**
Title: Optimal sequence in metastatic HER2+ breast cancer
Chair(s): Lisa Carey, US; Aleix Prat, ES

12:45 - 12:50 **Live introduction**
S. Not Yet Confirmed, , CH

12:50 - 13:05 **Decision-making in metastatic HER2+ breast cancer in 2021**
L. Carey, Chapel Hill, US

13:05 - 13:20 **HER2+ breast cancer: Clinical consequences of biologic heterogeneity**
A. Prat, Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES

13:20 - 13:35 **Making a chronic disease of metastatic HER2+ breast cancer: Are any cured?**
E. Winer, Dana-Farber Cancer Institute, Harvard Medical School, Boston, US

13:35 - 13:50 **Do CNS metastases in HER2+ breast cancer require a different systemic approach?**
T. Bachelot, Centre Léon Bérard, Lyon, FR

13:50 - 14:00 **Q&A and live discussion**
A. Speakers, , CH

12:45 - 13:45 **Type: Mini oral** **Channel 2**
Title: Mini Oral session 1
Chair(s): Sylvia Adams, US; Hiroji Iwata, JP

12:45 - 12:50 **Live introduction**
S. Not Yet Confirmed, , CH

12:50 - 12:55 **93MO - Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR⁺/HER2⁻; advanced breast cancer (ABC) treated with endocrine therapy (ET) & ribociclib (RIB)**
Y.S. Lu¹, N. El Saghir², S. Hurvitz³, D. Tripathy⁴, F. Cardoso⁵, M. Colleoni⁶, S. Campos-Gomez⁷, F. Franke⁸, R. Oregan⁹, C. Wang¹⁰, Y. Wang¹⁰, J.P. Zarate¹¹, A. Chakravartty¹², S.-A. Im¹³, ¹ Taipei City, TW, ²AUBMC - American University of Beirut Medical Center, Beirut, LB, ³UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵Champalimaud Foundation Cancer Center, Lisbon, PT, ⁶Istituto Europeo di Oncologia, Milan, IT, ⁷Centro Oncológico Estatal ISSEMYM, Toluca, MX, ⁸Centro de Pesquisa Clínica em Oncologia - ONCOSITE, Ijuí, BR, ⁹University of Wisconsin School of Medicine and Public Health Medical Physics, Madison, US, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Pharmaceuticals Corporation, Algiers, DZ, ¹²Novartis Pharmaceuticals

Corp., East Hanover, US, ¹³SNUH-Seoul National University Hospital, Seoul, KR

12:55 - 13:00

94MO - Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

A. Tibau¹, M.T. Martinez², M. Ramos³, L. De La Cruz-Merino⁴, A. Santaballa⁵, M. O' Connor⁶, N. Martinez-Jañez⁷, F. Moreno⁸, I. Fernandez Perez⁹, J.A. Virizuela¹⁰, J. Alarcón¹¹, J. De La Haba-Rodríguez¹², P. Sánchez-Rovira¹³, C.R. Albacar¹⁴, C. Bueno¹⁵, C. Kelly¹⁶, M. Casas¹⁷, S. Bezares¹⁸, L. Rosell¹⁸, J. Albanell¹⁹, ¹ Barcelona, ES, ²Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria-INCLIVA. GEICAM Breast Cancer Group, Valencia, ES, ³Centro Oncológico A Coruña. GEICAM Breast Cancer Group, A Coruna, ES, ⁴Hospital Universitario Virgen de la Macarena, Medicine Department-Universidad de Sevilla. GEICAM Breast Cancer Group, Sevilla, ES, ⁵Hospital Universitario y Politécnico La Fe. GEICAM Breast Cancer Group, Valencia, ES, ⁶University Hospital Waterford. Cancer Trials Ireland, Waterford City, IE, ⁷Hospital Universitario Ramón y Cajal. GEICAM Breast Cancer Group, Madrid, ES, ⁸Hospital Clínico Universitario San Carlos. GEICAM Breast Cancer Group, Madrid, ES, ⁹Hospital Alvaro Cunqueiro. GEICAM Breast Cancer Group, Vigo, ES, ¹⁰Hospital Quirón SaludSagrado Corazón. GEICAM Breast Cancer Group, Sevilla, ES, ¹¹Hospital Universitario Son Espases. GEICAM Breast Cancer Group, Palma de Mallorca, ES, ¹²Instituto Maimonides de Investigación Biomedica. Hospital Reina Sofía Hospital. Universidad de Córdoba. GEICAM Breast Cancer Group. CIBERONC-ISCI, Córdoba, ES, ¹³Hospital Universitario de Jaén. GEICAM Breast Cancer Group, Jaén, ES, ¹⁴Hospital Universitario Sant Joan de Reus. GEICAM Breast Cancer Group, Reus, ES, ¹⁵Hospital Universitario Infanta Cristina. GEICAM Breast Cancer Group, Madrid, ES, ¹⁶Cancer Trials Ireland. Mater Misericordiae University Hospital, Dublin, IE, ¹⁷GEICAM Breast Cancer Group, San Sebastián de los Reyes, ES, ¹⁸GEICAM Breast Cancer Group, San Sebastián de los Reyes, ES, ¹⁹Hospital del Mar, IMIM. GEICAM Breast Cancer Group. Pompeu Fabra University. CIBERONC-ISCI, Barcelona, ES

13:00 - 13:10

Invited Discussant 93MO and 94MO

P.A. Fasching, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nuremberg, Erlangen, DE

13:10 - 13:25

Q&A and live discussion

A. Speakers, , CH

13:25 - 13:30

LBA3 - Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial

L. Voorwerk, Netherlands Cancer Institute, Amsterdam, NL

13:30 - 13:38

Invited Discussant LBA3

S. Adams, New York City, US

13:38 - 13:45

Q&A and live discussion

A. Speakers, , CH

12:45 - 14:00 **Type: Educational session** **Channel 3**
Title: Precision medicine in breast cancer
Chair(s): Monica Arnedos, FR; Christos Sotiriou, BE

12:45 - 12:50 **Live introduction**
S. Not Yet Confirmed, , CH

12:50 - 13:05 **cfDNA testing for early detection of breast cancer and breast cancer relapse. Ready for prime time?**
N. Turner, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

13:05 - 13:20 **Genomic profiling for mBC patients: Which techniques? To whom, when and how often?**
M. Arnedos, Villejuif, FR

13:20 - 13:35 **Is there a role for molecular profiling in early breast cancer?**
C. Sotiriou, Brussels, BE

13:35 - 13:50 **Epigenetics in breast cancer: The comeback of an old friend?**
L. Magnani, London, GB

13:50 - 14:00 **Q&A and live discussion**
A. Speakers, , CH

14:15 - 15:30 **Type: Educational session** **Channel**
Title: Neoadjuvant/adjuvant treatment in triple negative breast cancer (TNBC) **1**
Chair(s): Javier Cortes Castan, ES; Rebecca Dent, SG

14:15 - 14:20 **Live introduction**
S. Not Yet Confirmed, , CH

14:20 - 14:35 **The role of the immune environment in TNBC**
R. Salgado, St-Augustinus Ziekenhuis, Wilrijk, BE

14:35 - 14:50 **How to treat patients with early TNBC on Monday morning**
R. Dent, Singapore, SG

14:50 - 15:05 **The role of immunotherapy in early TNBC**
P. Schmid, London, GB

15:05 - 15:20 **Potential new drugs with activity in metastatic TNBC**
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

15:20 - 15:30 **Q&A and live discussion**
A. Speakers, , CH

14:15 - 15:30 **Type: Proffered paper** **Channel 2**
Title: Proffered Paper session 1
Chair(s): Prudence Francis, AU; Lisa Carey, US

14:15 - 14:16 **Live introduction**
S. Not Yet Confirmed, , CH

14:16 - 14:26 **630 - Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeOPAL study**
S. Delaloge¹, S. Dureau², V. D'Hondt³, I. Desmoulins⁴, P.-E. Heudel⁵, F. Duhoux⁶, C. Levy⁷, F. Lerebours⁸, M.-A. Mouret-Reynier⁹, F. Dalenc¹⁰, J.-S. Frenel¹¹, C. Jouannaud¹², L. Venat-Bouvet¹³, S. Nguyen¹⁴, C. Callens¹⁵, D. Gentien², H. Manduzio¹⁶, A. Vincent-Salomon¹⁵, J. Lemonnier¹⁶, P. Cottu¹⁵, ¹Institut Gustave Roussy, Paris, FR, ²Curie Institute, Paris, FR, ³ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁴Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ⁷Centre Francois Baclesse, Caen, FR, ⁸Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ⁹Centre Jean-Perrin, Clermont Ferrand, FR, ¹⁰Institut Claudius Regaud - IUCT Oncopole, Toulouse, FR, ¹¹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹²Institut de Cancérologie Jean-Godinot, Reims, FR, ¹³CHU Limoges, Limoges, FR, ¹⁴Centre Hospitalier de Pau, Pau, FR, ¹⁵Institut Curie, Paris, FR,

16UNICANCER, Paris, FR

- 14:26 - 14:36 **910 - Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings**
P.A. Fasching¹, A. Bardia², A. Nusch³, G. Jerusalem⁴, A. Chan⁵, N. El Saghir⁶, E. Alba Conejo⁷, S.-A. Im⁸, W. Janni⁹, D. Chandiwana¹⁰, B. Lanoue¹¹, A. Thuerigen¹², E. Gu¹³, N. Harbeck¹⁴, ¹University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nuremberg, Erlangen, DE, ²Massachusetts General Hospital Cancer Center, Boston, US, ³Onkologische Praxis Velbert, Velbert, DE, ⁴CHU Liège and Liège University, Liège, BE, ⁵Breast Cancer Research Centre BCRC - WA, Nedlands, AU, ⁶AUBMC - American University of Beirut Medical Center, Beirut, LB, ⁷Hospital Universitario Virgen de la Victoria, Málaga, ES, ⁸SNUH-Seoul National University Hospital, Seoul, KR, ⁹Ulm Medical University, Ulm, DE, ¹⁰Novartis, East Hanover, US, ¹¹Novartis Pharmaceuticals Corp., East Hanover, US, ¹²Novartis Pharma AG, Basel, CH, ¹³Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁴Ludwig Maximilians University - Grosshadern, Munich, DE
- 14:36 - 14:46 **Invited Discussant 630 and 910**
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 14:46 - 14:53 **Q&A and live discussion**
A. Speakers, , CH
- 14:53 - 15:03 **10 - Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests**
V. Serra¹, A. Llop-Guevara¹, A. Pearson², C. Cruz¹, M. Castroviejo-Bermejo¹, N. Chopra², H. Tovey², C. Toms², D. Kriplani², H. Gevensleben², R. Roylance³, S. Chan⁴, A. Tutt⁵, A. Skene⁶, A. Evans⁷, H. Davies⁸, J. Bliss⁵, S. Nik-Zainal⁹, J. Balmaña¹, N. Turner¹⁰, ¹Vall d'Hebron Institute of Oncology, Barcelona, ES, ²The Institute of Cancer Research, London, GB, ³UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ⁴Nottingham University Hospital Trust, Nottingham, GB, ⁵ICR - Institute of Cancer Research, London, GB, ⁶Royal Bournemouth Hospital, Bournemouth, GB, ⁷Poole Hospital NHS Foundation Trust, Poole, GB, ⁸University of Cambridge, Cambridge, GB, ⁹Addenbrooke's Treatment Centre, Cambridge, GB, ¹⁰The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 15:03 - 15:13 **20 - Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial**
A. Llop-Guevara¹, V. Vladimirova², A. Schneeweiss³, G. Villacampa¹, T. Karn⁴, D.-M. Zahm⁵, A. Herencia-Roperio¹, P. Jank⁶, M. Van Mackelenbergh⁷, P.A. Fasching⁸, F. Marmé⁹, E. Stickeler¹⁰, C. Schem¹¹, R. Dienstmann¹, S. Florian¹², V. Nekljudova², J. Balmaña¹, C. Denkert¹³, S. Loibl², V. Serra¹, ¹Vall d'Hebron Institute of Oncology, Barcelona, ES, ²GBG, Neu-Isenburg, DE, ³Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE, ⁴Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁵SRH Wald-Klinikum Gera, Gera,

DE, ⁶Philipps-Universität Marburg, Marburg, DE, ⁷Universitätsklinikum Schleswig-Holstein, Kiel, DE, ⁸University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, University Erlangen-Nuremberg, Erlangen, DE, ⁹UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ¹⁰Uniklinik RWTH Aachen, Aachen, DE, ¹¹Mammazentrum Hamburg, Hamburg, DE, ¹²Charité - Universitätsmedizin Berlin, Berlin, DE, ¹³Philipps-University Marburg, Marburg, DE

15:13 - 15:23 **Invited Discussant 10 and 20**

A. Tutt, ICR - Institute of Cancer Research, London, GB

15:23 - 15:30 **Q&A and live discussion**

A. Speakers, , CH

**14:15 - 15:30 Type: Young oncologist session
Title: YO Boxing session**

Channel 3

Chair(s): Matteo Lambertini, IT; Alexios Matikas, SE

14:15 - 14:20 **Live introduction**

S. Not Yet Confirmed, , CH

14:20 - 14:35 **Germline testing beyond BRCA: Do we need it? YES**

K. Punie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

14:35 - 14:50 **Germline testing beyond BRCA: Do we need it? NO**

J. Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, ES

14:50 - 15:05 **Should all breast cancer patients receiving AI be treated with bone-modifying agents regardless of age and baseline T-score? YES**

R. Coleman, Sheffield, GB

15:05 - 15:20 **Should all breast cancer patients receiving AI be treated with bone-modifying agents regardless of age and baseline T-score? NO**

M.V. Dieci, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

15:20 - 15:30 **Q&A and live discussion**

A. Speakers, , CH

15:45 - 17:00 **Type: Multidisciplinary tumour board** **Channel 1**
Title: Neoadjuvant/adjuvant treatment of HER2+
Chair(s): David Cameron, GB; Martine Piccart, BE

15:45 - 15:50 **Live introduction**
S. Not Yet Confirmed, , CH

15:50 - 16:05 **Evaluation of HER2 status: What else needs to be known**
A. Vincent-Salomon, Institut Curie, Paris, FR

16:05 - 16:20 **Can we cure oligometastatic HER2+ disease?**
D. Cameron, Edinburgh, GB

16:20 - 16:35 **Should we maximise HER2 blockade for triple positive disease?**
M. Piccart, Institute Jules Bordet, Brussels, BE

16:35 - 16:50 **Surgery in the time of pathological complete responses: How to adapt to better systemic therapy?**
H.-B. Lee, Seoul, US

16:50 - 17:00 **Q&A and live discussion**
A. Speakers, , CH

15:45 - 17:00	Type: Educational session Title: Impact of ethnicity-based differences in breast cancer Chair(s): Seock-Ah Im, KR; Ellen Copson, GB	Channel 2
15:45 - 15:50	Live introduction <u>S. Not Yet Confirmed</u> , , CH	
15:50 - 16:05	Ethnicity, clinico-pathologic difference and outcome of young breast cancer patients <u>E. Copson</u> , Southampton, GB	
16:05 - 16:20	Impact of ethnicity on efficacy and toxicity of cyclin d kinase 4/6 inhibitors with endocrine therapy <u>S.-A. Im</u> , SNUH-Seoul National University Hospital, Seoul, KR	
16:20 - 16:35	Pharmacokinetic differences and ethnic variability in tolerance of cytotoxic drugs <u>R. Danesi</u> , Pisa, IT	
16:35 - 16:50	Ethnic differences in hereditary breast cancer focusing on BRCAmt in PARPi era <u>Y.H. Park</u> , Seoul, US	
16:50 - 17:00	Q&A and live discussion <u>A. Speakers</u> , , CH	

15:45 - 17:00 **Type: Educational session** **Channel 3**
Title: Optimal sequence in metastatic ER+ breast cancer
Chair(s): Nadia Harbeck, DE; Fatima Cardoso, PT

15:45 - 15:50 **Live introduction**
S. Not Yet Confirmed, , CH

15:50 - 16:05 **Use of biomarkers to guide treatment selection**
M. Liu, Rochester, US

16:05 - 16:20 **CDK 4/6i: The established first-line standard?**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

16:20 - 16:35 **Progression after CDK 4/6i: How to sequence approved options**
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

16:35 - 16:50 **Progression after CDK 4/6i: New kids on the block**
P. Aftimos, Institute Jules Bordet, Brussels, BE

16:50 - 17:00 **Q&A and live discussion**
A. Speakers, , CH

17:15 - 18:30 **Type: Proffered paper** **Channel 1**
Title: Best abstracts
Chair(s): Giuseppe Curigliano, IT; Sung-Bae Kim, KR; Sibylle Loibl, DE

17:15 - 17:16 **Live introduction**
S. Not Yet Confirmed, , CH

17:16 - 17:28 **410 - Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial**
P.F. Conte¹, A. Frassoldati², G. Bisagni³, A. Brandes⁴, M. Donadio⁵, O. Garrone⁶, F. Piacentini⁷, L. Cavanna⁸, F. Giotta⁹, M. Aieta¹⁰, V. Gebbia¹¹, A. Musolino¹², A. Ferro¹³, S. Danese¹⁴, C. Zamagni¹⁵, O. Nanni¹⁶, M.V. Dieci¹⁷, R. Vicini¹⁸, S. Balduzzi¹⁹, V. Guarneri²⁰, ¹University of Padova, Padova, IT, ²Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, ³Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁴Ospedale Bellaria, Bologna, IT, ⁵AOU Città della Salute e della Scienza Torino, Torino, IT, ⁶Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, ⁷Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁸Area Ospedaliera di Piacenza - Ospedale Guglielmo da Saliceto - AUSL Piacenza, Piacenza, IT, ⁹Istituto Oncologico Bari, Bari, IT, ¹⁰Centro di Riferimento Oncologico Basilicata IRCCS, Rionero in Vulture, IT, ¹¹Casa di Cura La Maddalena Dipartimento Oncologico di III livello, Palermo, IT, ¹²Azienda Ospedaliera di Parma, Parma, IT, ¹³Ospedale Santa Chiara - APSS, Trento, IT, ¹⁴S Anna Hospital, torino, IT, ¹⁵AOU Policlinico S. Orsola-Malpighi, F.Addarii,

Bologna, IT, ¹⁶Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ¹⁷IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁸azienda ospedaliero universitaria di modena, modena, IT, ¹⁹universita di modena e reggio emilia, modena, IT, ²⁰Istituto Oncologico Veneto IRCCS, Padova, IT

17:28 - 17:40 **420 - Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)**

O. Metzger¹, C. Lambertini², I. Krop³, G. Lewis Phillips⁴, C. Perou⁵, F. Symmans⁶, I. Melero⁷, N. Harbeck⁸, E. Winer⁹, S.-A. Im¹⁰, C. Barrios¹¹, H. Bonnefoi¹², J. Gralow¹³, P. Ellis¹⁴, L. Gianni¹⁵, M. Toi¹⁶, S. Swain¹⁷, T. Boulet², C. Song⁴, S. De Haas², ¹ Boston, US, ²F. Hoffmann-La Roche Ltd., Basel, CH, ³Dana-Farber Cancer Institute, Boston, US, ⁴Genentech, Inc., South San Francisco, US, ⁵Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, US, ⁶University of Texas MD Anderson Cancer Center, Houston, US, ⁷Clinica Universitaria de Navarra, Pamplona, ES, ⁸Ludwig Maximilians University - Grosshadern, Munich, DE, ⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ¹⁰SNUH-Seoul National University Hospital, Seoul, KR, ¹¹Oncoclínicas, HSL, PUCRS, Porto Alegre, BR, ¹²Institut Bergonié Unicancer and Bordeaux University, Bordeaux, FR, ¹³University of Washington Seattle Cancer Care Alliance, Seattle, US, ¹⁴Guy's Hospital and Sarah Cannon Research Institute, London, GB, ¹⁵Fondazione Michelangelo, Milano, IT, ¹⁶Kyoto University-Graduate school of medicine, Kyoto, JP, ¹⁷Georgetown University Medical Center, Washington, US

17:40 - 17:52 **430 - Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial**

C. Dang¹, M. Ewer², S. Delaloge³, J.-M. Ferrero⁴, R. Colomer⁵, L. De La Cruz Merino⁶, K. Dadswell⁷, M. Verrill⁸, D. Eiger⁹, S. Sarkar⁷, S. De Haas¹⁰, E. Restuccia¹¹, S. Swain¹², ¹ New York, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Institut Gustave Roussy, Paris, FR, ⁴Centre Antoine Lacassagne, Nice, FR, ⁵Hospital Universitario La Princesa, Madrid, ES, ⁶Hospital Universitario Virgen Macarena, Seville, ES, ⁷Roche Products Limited, Welwyn Garden City, GB, ⁸Northern Centre For Cancer Care, Newcastle Upon Tyne, GB, ⁹F. Hoffman-La Roche, Basel, CH, ¹⁰F. Hoffmann-La Roche Ltd., Basel, CH, ¹¹F. Hoffmann-La Roche Ltd, Basel, CH, ¹²Georgetown University Medical Center, Washington, US

17:52 - 18:07 **Invited Discussant 410, 420 and 430**

E. De Azambuja, Brussels, BE

18:07 - 18:30 **Q&A and live discussion**

A. Speakers, , CH

18:45 - 19:45 **Type: YO Virtual Lounge Discussions** **Lounge**
Title: Building your career between the clinic and the lab in the competitive breast cancer field
Chair(s): Matteo Lambertini, IT

18:45 - 19:45 **Mentor**
A. Prat, Medical Oncology Department, Hospital Clínic de Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Medicine Department, University of Barcelona, Barcelona, ES

19:45 - 19:45 **Mentor**
M. Arnedos, Villejuif, FR

08.05.2021

11:00 - 12:00 **Type: YO Virtual Lounge Discussions** **Lounge**
Title: Breast cancer molecular tumor boards for the practicing oncologist: Ready for prime time?
Chair(s): Alexios Matikas, SE

11:00 - 12:00 **Mentor**
P. Aftimos, Institute Jules Bordet, Brussels, BE

12:00 - 12:00 **Mentor**
M. Oliveira, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

12:00 - 12:30 **Type: Keynote** **Channel 1**
Title: ESMO Breast Cancer 2020 Award lecture
Chair(s): Giuseppe Curigliano, IT

12:00 - 12:05 **Introduction to the ESMO Breast Cancer 2020 Award lecture**
G. Curigliano, European Institute of Oncology, Milan, IT

12:05 - 12:30 **Title to be announced**
S. Not Yet Confirmed, , CH

12:45 - 14:00 **Type: Educational session** **Channel 1**
Title: Immunotherapy in metastatic breast cancer (mBC)
Chair(s): Marleen Kok, NL; Sherene Loi, AU

12:45 - 12:50 **Live introduction**
S. Not Yet Confirmed, , CH

12:50 - 13:10 **First-line chemo-IO for mTNBC**
G. Curigliano, European Institute of Oncology, Milan, IT

13:10 - 13:30 **Future of PD-1 blockade for ER+ and HER2+ mBC**
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

13:30 - 13:50 **Potential of IO-IO combinations for mBC**
M. Kok, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

13:50 - 14:00 **Q&A and live discussion**
A. Speakers, , CH

12:45 - 14:00 **Type: Mini oral** **Channel 2**
Title: Mini Oral session 2

Chair(s): Yen Shen Lu, TW; Frédérique Penault-Llorca, FR

- 12:45 - 12:46 **Live introduction**
S. Not Yet Confirmed, , CH
- 12:46 - 12:51 **LBA4 - Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial**
A. Bardia, Massachusetts General Hospital Cancer Center, Boston, US
- 12:51 - 12:56 **95MO - Characteristics of patients with brain metastases from HER2-positive breast cancer**
E. Laakmann¹, I. Witzel², T. Neunhöffer³, T.-W. Park-Simon⁴, R. Weide⁵, K. Riecke², A. Polasik⁶, M. Schmidt⁷, J. Puppe⁸, C. Mundhenke⁹, K. Lübke¹⁰, T. Hesse¹¹, M. Thill¹², D.-M. Zahm¹³, C. Denkert¹⁴, T. Fehm¹⁵, V. Nekljudova¹⁶, J. Rey¹⁷, S. Loibl¹⁶, V. Mueller^{2, 1}
Hamburg, DE, ²UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ³HELIOS Dr. Host Schmidt Kliniken, Wiesbaden, DE, ⁴Medizinische Hochschule Hannover (MHH), Hannover, DE, ⁵Praxis für Hämatologie und Onkologie Koblenz, Koblenz, DE, ⁶Universitätsklinikum Ulm, Ulm, DE, ⁷Universitätsmedizin Mainz, Mainz, DE, ⁸Universitätsklinikum Köln, Köln, DE, ⁹Klinikum Bayreuth GmbH, Bayreuth, DE, ¹⁰Diakovere Henriettenstift, Hannover, DE, ¹¹Agaplesion Diakonieklinikum, Rotenburg, DE, ¹²Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, ¹³SRH Wald-Klinikum Gera, Gera, DE, ¹⁴Philipps-University Marburg, Marburg, DE, ¹⁵Universitätsklinikum Düsseldorf, Düsseldorf, DE, ¹⁶GBG, Neu-Isenburg, DE, ¹⁷German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE
- 12:56 - 13:01 **4MO_PR - HER2-low breast cancer: Evolution from primary breast cancer to relapse**
F. Miglietta¹, G. Griguolo¹, M. Bottosso², T. Giarratano³, M. Lo Mele⁴, M. Fassan¹, M. Cacciatore⁵, E. Genovesi¹, D. De Bartolo¹, G. Vernaci³, P.F. Conte¹, V. Guarneri⁶, M.V. Dieci³, ¹University of Padova, Padova, IT, ²Padova, IT, ³I OV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴University Hospital of Padova, Padova, IT, ⁵Treviso General Hospital, Treviso, IT, ⁶Istituto Oncologico Veneto IRCCS, Padova, IT
- 13:01 - 13:13 **Invited Discussant LBA4, 95MO and 4MO_PR**
H. Iwata, Aichi Cancer Center Hospital, Nagoya, JP
- 13:13 - 13:27 **Q&A and live discussion**
A. Speakers, , CH
- 13:27 - 13:32 **LBA1 - 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature**
A. Johansson, Karolinska Institute, Stockholm, SE
- 13:32 - 13:37 **96MO - A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1**

J. Rodon¹, D. Demanse², H. Rugo³, F. André⁴, F. Janku⁵, I. Mayer⁶, H. Burris⁷, R. Simo⁸, A. Farooki⁹, H. Hu¹⁰, I. Lorenzo¹¹, C. Quadt¹², D. Juric¹³, ¹ Houston, US, ²Novartis Pharma AG, Basel, CH, ³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁶Vanderbilt-Ingram Cancer Center, Nashville, US, ⁷Sarah Cannon Research Institute, Nashville, US, ⁸Autonomous University of Barcelona, Barcelona, ES, ⁹Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Farmacéutica SA, Madrid, ES, ¹²Novartis International AG - Basel, Basel, CH, ¹³Massachusetts General Hospital Cancer Center, Boston, US

13:37 - 13:47 **Invited Discussant LBA1 and 96MO**

P. Francis, Melbourne, AU

13:47 - 14:00 **Q&A and live discussion**

A. Speakers, , CH

12:45 - 14:00	Type: Young oncologist session Title: YOC Forum - The future of academic research in oncology: Is there a role for young oncologists? Chair(s): Matteo Lambertini, IT; Kevin Punie, BE	Channel 3
---------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------

12:45 - 12:50 **Live introduction**

S. Not Yet Confirmed, , CH

12:50 - 13:05 **Challenges and opportunities: Key rules to get involved**

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

13:05 - 13:20 **The crucial role of mentorship and fellowships**

A. Matikas, Karolinska Institutet - Bioclinicum, Solna, SE

13:20 - 13:35 **Why join a large cooperative group? Let's make a BIG example**

D. Fumagalli, Brussels, BE

13:35 - 13:50 **Tips and tricks to get your idea funded by pharma**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

13:50 - 14:00 **Q&A and live discussion**

A. Speakers, , CH

15:00 - 16:15	Type: Educational session Title: Optimizing the management of premenopausal women with early breast cancer Chair(s): Lucia Del Mastro, IT; Olivia Pagani, CH	Channel 1
15:00 - 15:05	Live introduction <u>S. Not Yet Confirmed</u> , , CH	
15:05 - 15:20	Optimal adjuvant/neoadjuvant chemotherapy in triple negative subtype with or without gBRCA mutation <u>S.-B. Kim</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
15:20 - 15:35	Adjuvant chemotherapy in hormone-receptor positive tumours: Who to treat and which regimen? <u>S. Delaloge</u> , Institut Gustave Roussy, Paris, FR	
15:35 - 15:50	Type and duration of endocrine therapy in hormone receptor positive tumours <u>O. Pagani</u> , HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH	
15:50 - 16:05	Preserving fertility in young patients <u>L. Del Mastro</u> , Genova, IT	
16:05 - 16:15	Q&A and live discussion <u>A. Speakers</u> , , CH	

15:00 - 16:15	Type: Educational session Title: Brain mets management in HER2+ and triple negative breast cancer Chair(s): Volkmar Mueller, DE; Yen Shen Lu, TW	Channel 2
15:00 - 15:05	Live introduction <u>S. Not Yet Confirmed</u> , , CH	
15:05 - 15:20	The updated role of radiotherapy for breast cancer with brain metastases <u>J. Jung</u> , Seoul, KR	
15:20 - 15:35	HER2 targeting agents for treatment of HER2+ breast cancer with brain mets <u>V. Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
15:35 - 15:50	Anti-angiogenesis therapy for breast cancer with brain or leptomeningeal mets <u>Y.S. Lu</u> , Taipei City, TW	
15:50 - 16:05	Emerging treatments for breast cancer with brain metastases <u>A. Awada</u> , Brussels, BE	
16:05 - 16:15	Q&A and live discussion <u>A. Speakers</u> , , CH	

15:00 - 16:15 **Type: Educational session** **Channel 3**
Title: Testing recommendation in breast cancer
Chair(s): Frédérique Penault-Llorca, FR; Carsten Denkert, DE

15:00 - 15:05 **Live introduction**
S. Not Yet Confirmed, , CH

15:05 - 15:20 **State of art for luminal eBC: Ki67 and/or prognostic gene expression signatures?**
G. Viale, Milan, IT

15:20 - 15:35 **Immunohistochemistry: The new IHC “low” categories (ER, HER2⋯.) and androgen receptor testing**
C. Denkert, Philipps-University Marburg, Marburg, DE

15:35 - 15:50 **Biomarkers for immunotherapy (PD-L1, TILs, IA⋯): How and when?**
F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

15:50 - 16:05 **Molecular testing algorithms for metastatic BC**
F. Rojo, Madrid, ES

16:05 - 16:15 **Q&A and live discussion**
A. Speakers, , CH

16:30 - 17:45 **Type: Educational session** **Channel 1**
Title: Adjuvant treatment early HER+ in breast cancer
Chair(s): Sara Tolaney, US; E.G. Elisabeth de Vries, NL

16:30 - 16:35 **Live introduction**
S. Not Yet Confirmed, , CH

16:35 - 16:50 **Current standard approaches for early stage HER2+ disease**
S. Hurvitz, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

16:50 - 17:05 **How low should we go? Treatment for stage I HER2+ disease**
S. Tolaney, Dana-Farber Cancer Institute, Harvard Medical School, Boston, US

17:05 - 17:20 **Can imaging help tailor preoperative HER2-directed therapy?**
E.G.E. De Vries, Groningen, NL

17:20 - 17:35 **The path ahead: De-escalating and escalating care for early stage HER2+ disease**
S. Loibl, GBG, Neu-Isenburg, DE

17:35 - 17:45 **Q&A and live discussion**
A. Speakers, , CH

16:30 - 17:45 **Type: Proffered paper** **Channel 2**
Title: Proffered Paper session 2
Chair(s): Suzette Delaloge, FR; David Cameron, GB

16:30 - 16:31 **Live introduction**
S. Not Yet Confirmed, , CH

16:31 - 16:41 **LBA2 - Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial**
M. Graeser, Mönchengladbach, DE

16:41 - 16:51 **30 - Spatial analysis of lymphocytes and fibroblasts identifies biological relevant patterns in estrogen receptor positive breast cancer**
I. Nederlof¹, S. Hajizadeh², F. Sobhani³, S. Raza⁴, C. Desmedt⁵, R. Salgado⁶, M. Kok⁷, Y. Yuan³, H. Horlings², ¹ Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³The Institute of Cancer Research, London, GB, ⁴University of Warwick, Coventry, GB, ⁵KU Leuven, Leuven, BE, ⁶St-Augustinus Ziekenhuis, Wilrijk, BE, ⁷Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

16:51 - 17:01 **Invited Discussant LBA2 and 30**

C. Criscitiello, European Institute of Oncology, Milan, IT

17:01 - 17:08 **Q&A and live discussion**

A. Speakers, , CH

17:08 - 17:18 **920 - Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2⁺ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)**

C. Powell¹, S. Modi², H. Iwata³, S. Takahashi⁴, K. Nie⁵, A. Qin⁶, J. Singh⁶, C. Taitt⁶, S. Verma⁵, D.R. Camidge⁷, ¹ New York, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Aichi Cancer Center Hospital, Nagoya, JP, ⁴The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ⁵AstraZeneca Pharmaceuticals, Gaithersburg, US, ⁶Daiichi Sankyo, Inc, Basking Ridge, US, ⁷University of Colorado Cancer Center, Aurora, US

17:18 - 17:28 **440 - Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE**

M. Toi¹, N. Harbeck², J. Puig³, J. Cruz⁴, J.H. Seo⁵, M. Takahashi⁶, M. Hulstijn⁷, E. Twum⁷, A. Regev⁷, B. San Antonio⁷, D. Median⁸, M. Campone⁹, ¹Kyoto University-Graduate school of medicine, Kyoto, JP, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Centro Polivalente de Asistencia e Investigación Clínica, San Juan, AR, ⁴Hospital Universitario de Canarias. GEICAM, Spanish Breast Cancer Group, San Cristóbal de la Laguna, Santa Cruz de Tenerife, ES, ⁵Korea University Guro Hospital, Seoul, KR, ⁶Hokkaido Cancer Center, Sapporo, JP, ⁷Eli Lilly, Indianapolis, US, ⁸Spitalul Clinic Filantropia, București, RO, ⁹Institut de Cancérologie de l'Ouest - Site de Nantes -Centre René Gauducheau, SAINT-HERBLAIN, FR

17:28 - 17:38 **Invited Discussant 920 and 930**

H. Burstein, Boston, US

17:38 - 17:45 **Q&A and live discussion**

A. Speakers, , CH

16:30 - 17:45 **Type: Educational session** **Channel 3**
Title: Early drug development in breast cancer
Chair(s): Mafalda Oliveira, ES; Erika Hamilton, US

16:30 - 16:35 **Live introduction**
S. Not Yet Confirmed, , CH

16:35 - 16:50 **Epigenetic modulating drugs: Are we hitting the target?**
S. Minucci, Milan, IT

16:50 - 17:05 **Immunotherapy combos in TNBC**
M. Oliveira, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

17:05 - 17:20 **Next wave of ADCs: New targets, new drugs, new indications**

V. Boni, South Texas Accelerated Research Therapeutics (START) Madrid, Centro Integral Oncologico Clara Campal, Madrid, ES

17:20 - 17:35 **Challenges and pitfalls of early drug development in early breast cancer**
E. Hamilton, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US

17:35 - 17:45 **Q&A and live discussion**
A. Speakers, , CH

17:50 - 17:55 **Type: Closing session** **Channel 1**
Title: Live closing remarks
Chair(s): Giuseppe Curigliano, IT; Sibylle Loibl, DE; Sung-Bae Kim, KR

17:50 - 17:55 **Live closing remarks**